PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 1
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, 
PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY TO EVALUATE THE 
SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE 
ASCENDING ORAL DOSES OF PF-07258669 ADMINISTERED TO HEALTHY 
ADULT PARTICIPANTS
Study Intervention Number: PF-07258669
Study Intervention Name: N/A
US IND Number:EudraCT Number: 2020-004280-42
Protocol Number: C4541001
Phase: 1
Short Title: A Phase 1 Study of Single Ascending Doses of PF-07258669 in Healthy 
Adult Participants
This document and accompanying materials contain confidential information belonging to Pfizer.  Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in 
confidence and not copy or disclose it to others (except where required by applicable law) or use it for 
unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfizer must be 
promptly notified.CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary and Rationale for Changes
Amendment 1 09 November 2020 •Precautionary sentinel dosing will be 
used in each period of each cohort. The rationale for, and description of, sentinel dosing was added to Section 1.1 (Synopsis), Section 1.2 (Schema), Section 1.3 (Schedule of Activities), Section 2.3 (Benefit/Risk Assessment), Section 2.3.1 (Risk Assessment), Section 4.1 (Overall Design), Section 4.2 (ScientificRationale for Study Design), and Section 6.6.1 (Dose Escalation and Stopping Rules).
•The starting dose level for this study 
was reduced from 0.3 mg to 0.1 mg 
 
 
 
 
•  
 
 
 
 
 
Original protocol 07 October 2020 N/A
This amendment incorporates all revisions to date, including amendments made at therequest of country health authorities and IRBs/ECs.CCI
CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 3TABLE OF CONTENTS
LIST OF TABLES................................................................................................................. ....8
1. PROTOCOL  SUMMARY.....................................................................................................9
1.1. Sy nopsis .................................................................................................................. ..9
1.2. Schema .................................................................................................................... 11
1.3. Schedule of Activities .............................................................................................12
2. INTRODUCTION ...............................................................................................................1 5
2.1. Study R ationale .......................................................................................................15
2.2. Background .............................................................................................................15
2.2.1. MC4R and ....................................................................15
2.2.5. Nonclinical Safety ......................................................................................17
2.3. Benefit/Risk Assessment.........................................................................................17
2.3.2. Benefit Assessment.....................................................................................21
2.3.3. Overall Benefit/Risk Conclusion................................................................21
3. OBJECTIVES AND ENDPOINTS .....................................................................................214. STUDY DESIGN................................................................................................................. 22
4.1. Overall Design.........................................................................................................224.2. Scientific Rationale for Study Design.....................................................................224.3. Justification for Dose ..............................................................................................25
4.3.2. Human Exposure Stopping Limits..............................................................25
4.3.3. Rationale for Dose Selection ......................................................................26
4.4. End of Study Definition ..........................................................................................27
5. STUDY POPULATION ......................................................................................................27
5.1. Inclusion Criteria.....................................................................................................28
5.2. Exclusion Criteria....................................................................................................285.3. Lifestyle Cons iderations..........................................................................................31CCI
CCI
CCICCI

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 45.3.1. Meals and Dietary  Restrictions ...................................................................31
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................31
5.3.3. Activity .......................................................................................................31
5.3.4. Contraception ..............................................................................................32
5.4. Screen Failures ........................................................................................................32
6. STUDY INTERVENTION ..................................................................................................33
6.1. Study  Intervention(s) Administered ........................................................................33
6.1.1. Administration ............................................................................................33
6.2. Preparation/Handling/Storage/Ac countability ........................................................33
6.2.1. Preparation and Dispensing ........................................................................34
6.3. Measures to Minimiz e Bias: Randomization and Blinding .....................................35
6.3.1. A llocation to Study Intervention ................................................................35
6.3.2. Breaking the Blind ......................................................................................35
6.4. Study  Intervention Compliance ...............................................................................35
6.5. Concomitant Therapy ..............................................................................................36
6.5.1. Rescue Medicine .........................................................................................36
6.6. Dose Modification ...................................................................................................36
6.6.1. Dose Escalation and Stoppin
g Rules ..........................................................36
6.7. I ntervention After the End of the Study ..................................................................38
7. DI SCONTINUATION O F STUDY INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................38
7.1. Discontinuation of Study  Intervention ....................................................................38
7.2. Participa nt Discontinuation/Withdrawal From the Study .......................................39
7.2.1. Withdrawal of
Consent...............................................................................40
7.3. L ost to Follow -
up ....................................................................................................40
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................41
8.1. Efficacy  Assessme nts..............................................................................................42
8.2. Safet y Assessments .................................................................................................42
8.2.1. Phy sical Examinations ................................................................................42
8.2.2. Neurological Examinations ................................ ................................ ........ 43
8.2.3. Vital Signs ..................................................................................................43
8.2.4. Respiratory  Rate ................................ ................................ ......................... 44

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 58.2.5. Oral Body Temperature ..............................................................................44
8.2.6. Electrocardiograms.....................................................................................44
8.2.6.1. Continuous Cardiac Monitoring by Telemetry .........................45
8.2.7. Clinical Safety La boratory Asse ssments ....................................................45
8.2.8. COVID-19 Specific Assessments...............................................................46
8.3. Adverse Events and Serious Adverse Events..........................................................46
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......47
8.3.1.1. Reporting SAEs to Pfizer Safety...............................................478.3.1.2. Recording Nonserious AEs and SAEs on the CRF...................47
8.3.2. Method of Detecting AEs and SAEs ..........................................................488.3.3. Follow-up of AEs and SAEs.......................................................................488.3.4. Regulatory Reporting Requirements for SAEs...........................................488.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational 
Exposure ..........................................................................................................48
8.3.5.1. Exposure During Pregnancy......................................................498.3.5.2. Exposure During Breastfeeding ................................................508.3.5.3. Occupational Exposure .............................................................51
8.3.6. Cardiovascular and Death Events...............................................................518.3.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................51
8.3.8. Adverse Events of Special Interest.............................................................51
8.3.8.1. Lack of Efficacy........................................................................51
8.3.9. Medical Device Deficiencies......................................................................518.3.10. Medication Errors .....................................................................................51
8.4. Treatment of Overdose............................................................................................52
8.7. Genetics................................................................................................................... 54
8.7.1. Specified Genetics ......................................................................................54
CCI

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 68.7.2. Banked Biospecimens for Genetics ............................................................54
8.8.2. Banked Biospecimens for Biomarkers .......................................................56
8.8.3. Specified Gene Expression (RNA) Research .............................................568.8.4. Specified Protein Research .........................................................................568.8.5. Specified Metabolomic Research ...............................................................56
8.9. Immunogenicity Assessments .................................................................................568.10. Health Economics .................................................................................................56
9. STATISTICAL C ONSIDERATIONS ................................................................................56
9.1. Statistical Hypotheses .............................................................................................569.2. Sample Size Determination.....................................................................................579.3. Analysis Sets ...........................................................................................................579.4. Statistical Analyses .................................................................................................57
9.4.1. Safety Analys es ..........................................................................................58
9.4.1.1. Electrocardiogram Interval Analyses ........................................58
9.4.2. PK Analyses................................................................................................59
9.4.2.1. Derivation of PK Parameters.....................................................599.4.2.2. Statistical Methods for PK Data................................................60
9.4.3. Other Analyses............................................................................................60
9.5. Interim Analyses .....................................................................................................609.6. Data Monitoring Committee or Other Independent Oversight Committee.............60
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................61
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............61
10.1.1. Regulatory and Ethical Considerations ....................................................61
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................61
10.1.2. Financial Disclosure .................................................................................62CCI

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 710.1.3. Informed Consent Process ........................................................................62
10.1.4. Data Protection .........................................................................................6310.1.5. Dissemination of Clinical Study Data ......................................................6310.1.6. Data Quality Assurance ............................................................................6510.1.7. Source Documents....................................................................................6610.1.8. Study and Site Start and Closure ..............................................................6610.1.9. Publication Policy.....................................................................................6710.1.10. Sponsor’s Qualified Medical Personnel .................................................68
10.2. Appendix 2: Clinical Laboratory Tests .................................................................6910.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ......................................................................70
10.3.1. Definition of AE .......................................................................................7010.3.2. Definition of SAE.....................................................................................7110.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.......................7310.3.4. Reporting of SAEs....................................................................................76
10.4. Appendix 4: Contraceptive Guidance ...................................................................77
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................7710.4.2. Female Participant Reproductive Inclusion Criteria.................................7710.4.3. Woman of Childbearing Potential ............................................................7710.4.4. Contraception Methods.............................................................................78
10.5. Appendix 5: Genetics ............................................................................................8010.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments ........8110.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................83
10.10. Appendix 10: Abbreviations ...............................................................................89
11. REFERENCES ................................................................................................................. .93
CCI

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 8LIST OF TABLES
Table 2. Plasma PK Parameters..............................................................................59
Table 3. Protocol Required Safety Laboratory Assessments..................................69CCI

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 91. PROTOCOL SUMMARY
1.1. Synopsis Short Title: A Phase 1 Study of Single Ascending Doses of PF-07258669 in Healthy Adult 
Participants
Rationale: This study is the first clinical study with PF-07258669. The safety, tolerability, 
and plasma PK of PF-07258669 after administration of escalating, single, oral doses will be evaluated.
Objectives and Endpoints:
Objectives Endpoints
Primary: Primary: 
•To evaluate the safety and tolerability of single 
ascending doses of PF-07258669 administered orally to healthy adult participants.•Assessment of adverse events, clinical safety 
laboratory tests, vital signs, continuous cardiac monitoring, 12-lead electrocardiograms, respiratory rate, oral body temperature, physicalexaminations, and neurological examinations.
Secondary: Secondary: 
•To evaluate the pharmacokinetics of 
PF-07258669 following single doses of PF-07258669 administered orally to healthy adult participants.•PK parameters derived from plasma PF-07258669
concentrations: C
max, AUC last, AUC inf, Tmax, and 
t½, if data permit.
 
 
 
  
 
 
  
 
 
 
 
  
Overall Design: This study is a randomized, investigator- and participant-blind, 
sponsor-open, placebo-controlled, first-in-human, single ascending oral dose study of PF-07258669 administered to healthy adult participants. Precautionary sentinel dosing will be used in each period of each cohort. Two participants (1 receiving PF-07258669 and CCI
PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 101receiving placebo) within a period will be dosed initially  before the remaining participants 
of that period are dosed. Safety  and tolerability  data through at least 24 hours post -dose for 
the sentinel participants will be r eviewed prior t o dosing the remaini ng participants of that 
period.
Number of Participants: A maximu mof approximately  24participan ts will be random ized 
in this study (8 per cohort) . 
Intervention Groups and Duration : The study  interventio ns include PF -
07258669 and 
plac
ebo. B oth wil lbe administered as extemporaneously -prepared solutions or susp ensions 
for oral administration. Participants will receive single doses ineach period of the 
study . 
Data Monitoring Committee or Other Independe nt Oversight Comm ittee:No.
Statistical Methods: Thesample size has been chosen based on the need to minimize first
exposure to humans of a new chemicalentity  and the requirement to conduct adequate saf ety,
toleration , and PK assessments at each dose lev el.
All safet y analyses will beperfo rmed on thes afety analysis set, which is defined as all 
participants randoml yassigned to study  intervention and who receive a dose of study  
intervention.  Participa nts will be analy zed according to the product they  actually  received.
Safety  data will be presen ted in tabular and/or graphical format and summarized 
descriptivel y, whe
re appropriate. 
The PK paramet ers for PF ‑07258669 following oral dose administration w ill be derived from 
the plasma concentration ‑time profiles. PK parameters and conc entrations of PF-07258669 
will be descriptivel y summarized by dose and nominal time, as appropriate.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 111.2. Sch ema

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 121.3. Schedule of Activities
The SoA table provides an overview of the protocol visits and procedures.  Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. The investigator may schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to condu ct 
evaluations or assessments required to protect the well-being of the participant.
Visit IdentifieraScreening Period 1 to Period 4bFollow-Up ET/DC
Day -28 
to Day -2Day 
-1Day 1 Day 
2Day 
3Visit: 
Day 
8±2cContact: 
28-35
DayscHours After Dose 0d0.17 0.5 11.5 2 4 6 810 12 16 24 36 48
Informed consent and de mography X
Outpatient visit X X
Inpatient stay at CRU X → → →→→→→→→→→→→→ Xe
Review inclusion/exclusion criteria X Xf
Medical/medication histor y XXf
History of alcohol, tobacco, and illegal drug use X Xf
Contrace ption chec kgXX X XX X
COVID-19 questionnairehXX
COVID-19 testiXX X
COVID-19 body temperature check X X X X X X X X X
Physical exam (height and weight at Screening
only)jXX
Neurological examination X X X X X X X
Review concomitant treatments X X XX X
Respiratory rate X XXXXXX X X
Oral body temperature X XXXXXX X
12-Lead ECGkX X XXXXXXX X X X X X
S u p i n e  B P  a n d  P R X X XX XXXX X X X
Orthostatic (supine and standing) BP and PR X X X
Continuous cardiac telemetrylX→→→→→→→ X
Serious/nonserious AE monitoring X → → →→→→→→→→→→→→→→ → XX
Blinded study intervention administrationoXp
Blood Samples for:
Clinical safety laboratory tests, including lipid 
panelqXX X X X XCCI

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 13Visit IdentifieraScreening Period 1 to Period 4bFollow-Up ET/DC
Day -28 
to Day -2Day 
-1Day 1 Day 
2Day 
3Visit: 
Day 
8±2cContact: 
28-35
DayscHours After Dose 0d0.17 0.5 11.5 2 4 6 810 12 16 24 36 48
Serum FSHrX
HBcAb, HBsAg, HBsA b, HCVAb, HIV testing X
Pfizer Prep B2 banked samplesX
Pfizer Pre p D1.5 banked samplesX
PF-07258669 plasmapharmacokinetics X X X X X X X X X X X X XX X
Urine Samples for:
Urine drug test X X
Clinical safety laboratory testsqXX X X X X
Abbreviations: →= ongoing/continuous event; AE = adverse event; BP = blood pressure; CRU = clinical research unit; DC = discontinuation; ECG = electrocardiogram; 
ET = early termination; FSH = follicle stimulating hormone; HBcAb = hepatitis B core antibody; HBsAb = hepatitis B antibody; HBsA g = hepatitis B surface antigen; 
HCVAb = hepatitis C anti body; HIV = human immunodeficiency virus; PR = pulse rate.
a. Day relative to start of study treatment (Day 1).
b. There will be a washout interval of ≥7 days between doses within an individual participant.
c. Onsite follow-up visit to occur on Day 8 ±2 days in Period 4 only. Follow-up contact may occur via telephone contact and must o ccur 28-35 days after administration of the 
final dose of study intervention.
d. Day 1 activities at time=0 hours are prior to the dose, except for study treatment administration.e. Participants may be confined to the CRU after completion of Day 3 activities at the discretion of the investigator or if safet y, tolerability, or PK data dictate the need to 
prolong confinement in the CRU
.
f. Period 1 only. Review any changes from Screening.
g. Contraception only required for male study participants and is recommended for partners of male study participants who are WOCB P.
h. COVID-19 questionnaire includes check for suspected contact, risk zone, and COVID-19 related symptoms.
i. Testing for active COVID-19 infection via testing for SARS-CoV-2 viral dosing (using PCR). To meet PCRU practice, testing for  active COVID-19 infection will be
performed at screening, admission, and follow-up visit.
j. Complete physical examination must either be conducted at Screening or upon admission in Period 1 only.  Limited physical exa mination may be performed at admission on 
Day -1 in Period 1 if a complete physical examination is performed  at Screening.  Limited physical examinations may be performed  as appropriate at other times at the 
investigator’s discretion if there are findings during the previous examination or new/open adverse events.
k. Single 12-lead ECG at Screening. Triplicate 12-lead ECGs at all other timepoints.l. Baseline telemetry to be recorded for at least 2 hours prior to the first dose in Period 1 only.  This may be done immediatel y prior to dosing or at some 2 hour continuous 
interval in the 24 hours prior to dosing, as long as the participant is awake.  Post-dose telemetry will continue for 8 hours a fter dosing.CCI
CCI

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 14o. Precautionary sentinel dosing will be used in each period of each cohort. Two participants (1 receiving PF-07258669 and 1 recei ving placebo) within a period will be dosed 
initially before the remaining participants of that period are dosed. Safety and tolerability data through at least 24 hours po st-dose for the sentinel participants will be
reviewed prior to dosing the remaining participants of that period.
p. Participants should fast for at least 10 hours prior to dosing.q. Participants should fast for at least 12 hours prior to sample collection.r. Females who have been amenorrheic for at least 12 months.
s. Period 1 only. If not collected on the designated collection day, collect at the next available time when biospecimens are be ing collected in conjunction with a participant visit.C
C
C
C
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 152. INTRODUCTION
PF-07258669 is an MC4R antagonist  
2.1. Study Rationale 
This study will be the first time PF-07258669 is administered to humans. The purpose of the 
study is to evaluate the safety, tolerability, and PK of PF-07258669 following administration of single oral doses to healthy adult participants.
2.2. Background 
2.2.1. MC4R 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
CCICCI
CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
CCI
CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 172.2.5. Nonclinical Safety 
PF-07258669 was evaluated in a series of safety pharmacology and toxicity studies in rats 
and dogs up to 1 month in duration, as well as in a battery of genetic toxicity studies. 
 
 
 
 
 
 
 
 
 
The NOAELs in the pivotal 1-month toxicity studies 
were 100 mg/kg/day in rats (total C maxof 25,000 ng/mL and AUC of 224,000 ng•h/mL in 
males) and 30/60 mg/kg/day in male/female dogs (total C maxof 13,200 ng/mL and AUC of 
159,000 ng•h/mL in males).  PF-07258669 is not genotoxic  
  Details of the nonclinical safety program are provided in the investigator’s 
brochure.
2.3. Benefit/Risk Assessment
This study is the first time that PF-07258669 will be administered to humans and is designed 
primarily to generate safety, tolerability, and PK data for further clinical development.PF-07258669 is not expected to provide any clinical benefit to healthy participants. The purpose of the study is to provide the basis for further clinical development of PF-07258669
 
As of October 2020, no specific human risks have been identified;  
 The clinical impact of these 
potential risks will be minimized through the proposed cautious dose-escalation process wherein higher doses of PF-07258669 will be administered only after lower doses have been found to be well tolerated with an acceptable safety profile.  In addition, this study will use sentinel dosing and includes standard, intensive, inpatient monitoring of all participants following administration of single, oral doses of the study intervention.
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of PF-07258669 may be found in the investigator’s brochure, which is the SRSD for this study.CCI
CCI
CCI
CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 18 
 
  
 
 
 
 
  
  
 
 
 
 
  
 
 CCI
CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 19 
  
 
 
  
 
  
  
  
   
 
 
   
 
 
  CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 20 
 
 
 
  
  
 
 
 
 
 
 
 
 CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 212.3.2. Benefit Assessment
The participants in this study are not expected to obtain any specific benefit beyond 
contributing to the process of developing new therapies in an area of unmet need.  They will receive close monitoring of their safety via study procedures undertaken (eg, physical examinations, 12-lead ECGs, vital signs) which will occur as outlined in this protocol.  
2.3.3. Overall Benefit/Risk Conclusion
Based on the totality of available nonclinical data, and taking into account the measures 
taken to minimize risk to participants participating in this study, the overall benefit/risk profile supports clinical testing of PF-07258669.
3. OBJECTIVES AND ENDPOINTS
Objectives Endpoints
Primary: Primary: 
• To evaluate the safety and tolerability of single 
ascending doses of PF-07258669 administered 
orally to healthy adult participants.• Assessment of adverse events, clinical safety laboratory 
tests, vital signs, continuous cardiac monitoring, 
12-lead electrocardiograms, respiratory rate, oral body 
temperature, physical examinations, and neurological examinations.
Secondary: Secondary: 
• To evaluate the pharmacokinetics of PF-07258669 
following single doses of PF-07258669
administered orally to healthy adult participants.• PK parameters derived from plasma PF-07258669
concentrations: C max, AUC last, AUC inf, Tmax, and t ½, if 
data permit.
  
 
  
 
 
 
  
 
 
 CCI
PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 224.STUDY DESIGN
4.1.Overall Design
This study  is a randomized, investigator- and p articipant -blind, sponsor -open, 
placeb o-controlled, first -in-human, single ascending oral dose stud y of PF -07258669 
administered to health y adult participan ts. Up to approxim ately 24healthy  adult participants
(up to 3 cohorts of approximately  8 participa ntseach)will be enrolled in this stud y . Each 
participant is planned to undergo 4 treatment periods receiving 3 doses of PF -07258669 and 
1dose ofplacebo .
Precau tionary  sentinel dosing will be used in each period of each cohort. 
Two participants 
(1receiving PF -07258669 and 1 receiving placebo) wi thin a period will be dosed initially  
before the remaining participants of that period are dosed. Safety and tolerability  data 
through at least 24 hours post -dose for the sentinel participants will be reviewed prior to 
dosing the remaining participants of that period.
Dose level s will b eescalated to bracket the expected clinical dose range , but pr ojected
expos ures will not exceed the pre -defined human e xposure limits. The optional third cohort 
will only  be used if the objectives of the study  are not fulfilled in Cohort 1 and Cohor t
2. 
The total duration of participation from the screening visit t o the telepho ne follow-up contact
will be approximately  14weeks .
If a participant drops out before completing all study  periods within a cohort, or withdraws 
forreasons unrelated to the s afety of the study  intervention , the participant may be replaced 
atthediscreti on of the investigator and sponsor. The replac ement participant(s) may  or may  
not be required to complete all periods of the cohort in which they  are participating at the
discretion of the investigator and sponsor .
4.2.Scientific Rationale for Study Design
The p opula tionplanned for this study  will be hea lthy males and females of nonchildbearing 
potential . Female participants will be confirmed not to be of childbearing potential because 
embryo-fetal developmental toxicity  studies with PF -07258669 have not bee n conduc ted.  In 
male participants, appropriate measures are expected to be followed to minimize potential 
transfer of PF -07258669 via semen to partners (see Appendix 4 ).
Because this is the first time PF-07258669 will be administered to humans, an escalati ng 
single oral dose design is planned with careful assessment and ongoing review of safety, 
tolerability , and PK data of PF -07258669. Sentinel dosing will also be utilized in each 
perio d to ensure that safety and tole rability  data in a subset of 2 participants within each 
period supports testing additional participants.

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 23At each dose level, 6 participants are planned to receive PF-07258669 and 2 participants are 
planned to receive placebo with all participants at the end of the study having received 1 dose of placebo and 3 doses of PF-07258669. In addition, the highest anticipated C
maxand AUC 24
PF-07258669 will not exceed the pre-identified human exposure stopping limits nor exceed the highest feasible total daily dose of 2000 mg.
The design permits both within- and between-participant assessments of safety, tolerability, 
and PK. Furthermore, to permit an unbiased assessment of safety, the administration of both PF-07258669 and placebo in each period will be double-blinded to both site staff (except those involved in preparation of doses) as well as the participants. 
PK samples are planned to be collected over 48 hours post-dose. However, sampling times, 
duration of sampling, and/or the length of the washout period may be modified and/or extended if data generated in previous periods indicate that the half-life is longer than predicted.
There will be a washout interval of ≥7 days between doses within an individual participant, 
which is deemed sufficient based on the predicted PF-07258669 effective half-life  
. In addition, this interval accounts for the required time for review of 
the safety, tolerab ility, and PK data from each  dosing period before making a decision on the 
subsequent PF-07258669 dose to be evaluated. The planned doses in the escalation sequence (Table 1 and Section 1.2 ) may be modified or repeated, as guided by emerging safety, 
tolerability, and PK data but will follow the dose-escalation rules defined in Section 6.6.1 . 
 
 
 
 
 
 
 
 
 CCI
CCI
CCIC
CI

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although there is no suspicion of human teratogenicity based on the expected pharmacology 
of PF-07258669, human reproductive safety data are not available for PF-07258669. Therefore, the use of a highly effective method of contraception is required for male study participants and is recommended for partners of male study participants who are WOCBP(see Appendix 4 ).
Banked Biospecimens will be collected and stored for further analyses which may, for 
example, provide greater understanding of the study intervention.CCI
CCI
CCI
CCI
CCI

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 254.3. Justification for Dose
The proposed dose levels of PF-07258669 were derived based on cumulative nonclinical data
including in vitro and in vivo pharmacology and PK data and the completed nonclinical toxicity studies. Dose levels have been selected to bracket the expected clinical dose and exposure range, while considering uncertainty in the projected clinically efficacious dose. Dose levels beyond the starting dose may be modified based on emerging human safety, tolerability, and PK data in the current study.
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.2. Human Exposure Stopping Limits
The human exposure stopping limits are based on exposures observed in dogs in nonclinical 
toxicology studies and are corrected for species-dependent plasma protein binding between dog and human . CCI
CCI
CCI
CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 26 
 
 
The human AUC 24stopping limit is based on the NOAEL in male dogs (30 mg/kg/day) in 
4-week GLP toxicology study. The total AUC 24in male dogs was 159,000 ng·h/mL, which 
is the lowest AUC 24observed at the NOAEL across all toxicology studies in rats and dogs. 
After correcting for protein binding differences between dog and human, the human AUC 24
stopping limit is a total AUC 24of 212,000 ng·h/mL.
4.3.3. Rationale for Dose Selection
The safety, tolerab ility, and plasma PK of PF-07258669, a fter administration of single 
escalating oral doses across a wide dose/exposure range, will be evaluated in this study. Dosing will occur in the fasted state. The doses presented in Table 1 are projected based on nonclinical data and may be modified based on emerging human safety, tolerability, and PK data. Human PK parameter estimates, toxicokinetic data, and projected effective concentrations were used to establish the initial range of planned doses in this study. The projected human exposures assume dose-proportional increases in exposure within the planned dose range. 
  
 
 
 
 
 
 
 CCI
CCICCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 27Due to the  projected t ½of PF-07258669, plasma concentrations are expected to 
decrease rapidly upon attainment of C max.  
 
 
 
 
Therefore, given that the predicted exposure 
following a dose of 0.1 mg is not expected to result in any biological activity and affords large margins over the human C
maxstopping limit, it is deemed an appropriate starting dose 
level for this study.
The dose range to be studied was selected to account for uncertainties in the projected C eff
and the projected therapeutic dose, while also bracketing the expected clinically effective 
dose range in humans  and providing safety coverage for a wide range of PF-07258669 doses.
Assessment of the safety, tolerability, and PK after each single dose level will be conducted 
before escalating to the next dose level. The dose/exposure-escalation increments are planned to be up to approximately semi-logarithmic increases in exposure from the previous highest dose. The actual dose levels, target exposures, and/or dose level increments may be adjusted (higher or lower) during the study based on emerging human safety, tolerability, and PK data, but projected exposures will not exceed the predefined human exposure limits. If C
max-related adverse events are observed, split dosing may be used to potentially increase 
AUC without increasing C max. Dose levels may also be repeated if warranted.
4.4. End of Study Definition
A participant is considered to have completed the study if he/she has completed all phases of 
the study, including the last scheduled procedure shown in the SoA.
The end of the study is defined as the date of the last scheduled procedure shown in the SoA
for the last participant in the trial.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled.  The 
following eligibility criteria are designed to select participants for whom participation in the 
study is considered appropriate.  All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.CCI
CCICCI

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 285.1. Inclusion Criteria
Participants are eligible to be included in the study onl yif all of the following criteria apply:
Age and Sex :
1. F emale participants of nonchi ldbeari ng potential and males must be 18 to 55 y ears of 
age, inclusive, at the time o f signing the ICD .
Refer to Appendix 4forreproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2) participants.
Type of Participant and Disease Characteristics:
2.Femal e participants of no n-child bearin g potential and m ale participants and w ho are 
overtly
 healthy  as determined by  medical evaluation includ ing medical h istory, 
physical examination ,neurologic alexamination , laboratory  tests, and cardiac 
monitoring .
3.Partici pants who are willing to avoid dir ect sunlight exposure or a ny high inten sity 
ultraviolet light exp osure from admission to thefollow -up c ontact and to apply 
sunscreen/lotion with a high sun protection factor, as appropriate.
4.Participants who are willing a nd able to compl y with all schedul ed visits, treatment 
plan, laborat ory tests, life style considerat ions, and other study  procedures.
Weigh t:
5.BMI of 17. 5to30.5 kg/m2; and a total body  weight >50 kg (110 lb).
Informed Consent:
6.Capable of giving signed inf ormed consent as des cribed in 
Appen dix 1,which 
includes compliance with the requirements and restrictio ns listed in the ICDand in 
this protocol.
5.2.
Exclusion Criteria
Participants are excluded from the study  if any of the following criteria ap ply:
Medical Conditions:
1.Evid ence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal , cardiovascular, hepatic, ps ychiatric, neurologic al, or 
allergic disease (including drug alle rgies, but excluding untreated, asymptomatic, 
seasonal aller gies at the time of dosing),as well as presence of lipid panel 
abnormalities (eg,hypercholesterolemi a, hypertriglyceridemia ) .

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 292.Evidence of history  of orthostatic hy potension or sy mptomatic brad ycardia .
3.Any condition possibly  affecting drug absorption (eg, gastrectomy , chole cystectom y).  
4.History  of phototoxicity  or photosensi tivity .
5.History  of HIV infecti on, hepatitis B, or hepatitis C; positive testing for HIV, 
hepatitis B surface antigen ( HBsAg), hepatitis B core antibody (HB cAb)or 
hepatitis C antibody  (HCVAb ).  Hepatitis B vaccination is allowed. As an exception 
a positive HBsAb test due to hepatitis 
B vaccination is permissible.
6.Other medical or psy chiatric condition including recent (within t he past year),or 
active suici dal ideation /behavior ,or labo ratory  abnormality , or other condition or 
situation related to the COVID -19pandemic that may  increas e the risk of study  
participa tion or , in the investigator’s judgment, make the participant inap propriate for 
thestudy .
Prior /Con comitant Therapy:
7.Use of p rescription or non presc ription drugs and dietary  and herbal supplements 
within 7 days or5half-lives (whichever is longer) prior 
to the first dose of study  
intervention .  (Refer to Section 6.5 for addi tional det ails).
Prior/Concurrent Clinical Study Experience:
8.Previous administra tion w ith an inve stigational drug within 3 0days (or as determined 
by the local requirement) or 5half-lives preceding the firs t dose of 
study interventi on
used in this study  (whichever is lo nger). 
Diagnostic Assessments:
9.A positive urine drug test at screening or ad missionand confirmed b y a single repeat 
test, if deemed necessary .
10.Screening supine BP ≥140 mmHg (s ystolic) or ≥90mmHg (diastolic), foll owing at 
least 5 minute s of supine res t.  If BP is ≥140 mmHg (sy stolic ) or ≥90mmHg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant’s eligibility .
11.Current findings or docu mented past history  of blood pres sure values <90mmHg 
systolic or <50 mmHg diastolic.
12. 12 -lead ECG thatdemonstrates clinically relevant abnormalities that may affect 
participant safety or interpretation o f study results (eg, basel ine QTc interval 
>450 msec ,complete LBBB, signs of an acut e or indeterminate -age myocardial
infarction, ST -T interval changes suggestive of myo cardial ischemia, second -or 
third
-degree AVblock, or serious brady arrhy thmias or tac hyarrhy thmias).  If the 

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 30baseline uncorrected QT inte rval is >450 msec, this interval shoul d be rate -correcte d 
using the Fridericia method and the resulting QTcF should be used for decision 
making and reporting.   If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG 
should be re peated 2 more times and th e average of the 3 QTc or QRS val ues s hould 
be used to determine the participant’s eligibility .  Computer -interprete d ECGs should 
be overread b y a physician experienced in reading ECGs before excluding 
participants.
13.Participants w ith ANY of the following a bnormalities in clinica l laborato ry tests at 
screening, as assessed b y the study -specific laboratory  and confirmed b y a single 
repeat test, if deemed necessary :
AST or ALT level ≥1.0× ULN;
Total bilirubin level ≥1.5 ×ULN; partici pants with a history  of Gi lbert's 
syndrome may  have direct bilirubin measured and would be eligible for this study  
provided the direct bilirubin level is ≤UL N ;
Any lipid panel parameter ( ie, to tal cholesterol, trigl ycerides, HDL, and/or LDL)
≥1.25× ULN.
14.A positive COVID- 19 test.
Other Exclusions:
15.History of alcoho l abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of Screening.  Binge drinking is defined as a pattern of 
5(male) and 4 (female) or more alcoholic drinks i n about 2 hours .  As a general rule, 
alcohol inta ke should 
not e xceed 14 units per week (1 unit= 8ounces (240 mL) beer, 
1ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
16.Use of toba cco or nicotine containing products in excess of the equivalent of 
5cigarettes/day  or 2 chews of tobacco/day .
17. B lood donat ion (excluding plasma donations) of approximately  1pint (500 mL) or 
more within 60 days prior to dosing .
18.History  of sensitivity  to he parin or heparin- induced thrombocy topenia.
19.Unwilling or unable to comply  with the criter ia in the Lifesty le Considerati ons
section of this protocol.
20.Investigator site staff or Pfizer employ ees directl y involved in the conduct of t he 
study , site s taff otherwise superv ised by  the investigator, and t heir respective family  
members .

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 315.3.Lifestyle Considerati ons
The following guidelines are provided:
5.3.1. Meals and Dietary Restrictions
Participant s must abstain from all food and drink (except wa ter) at least 12hours 
prior to an y safety laboratory  evaluations and 10 hours prior to the collection of the 
predose PK s ample .
Water is permitted until 1 hour prior to study  intervention administration.  Water may  
be consumed without restriction beginnin g 1hour after dosing.  Noncaffeinate d 
drinks (except grapefruit or grapefruit -related citr us fruit juices —see below) may  be 
consumed with meals and the evening snack .
Lunch will be provided approximately  4
hours after dosing.
Dinner will be provided appro ximately  9to 10 hours after dosing.
An ev ening snack may  be permitt ed.
Participants will refrain from consuming red wine , grapefruit ,or grapefruit -related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from 7 days prior to the first 
dose of study  interventi onuntil collection o f the final PK blood sample.
While participants are confined, the irtotal daily  nutritiona l composition should be 
approximately  55% carbohy drate, 30% fat, and 15% protein.  The dail y caloric intake 
per participant shoul d not exceed app roximately  3200 kcal.
5.3.2. Caff eine, Alcohol, and Tobacco
Participant s will abst ain from caff eine-containing pr oduct s for ≥24hours prior to the 
start of dosing until collection of the final PK sample of each study  period. 
Participant s will abs tain from alcoho l for ≥24 hours prior (or as specified above for 
red wine) to admission to the CRU and c ontinue abstaining from alcoh ol until 
collection of the final PK sample of each study  period.  Participant s may  undergo an 
alcohol breath test or blood alcohol test at the discretion of the investigator.
Participant s will abstain from the use of tobacco - or nicotine- containing product s for 
≥24 hours prior to dosing and during confinement in the CRU.
5.3.3. Activity
Participants will abstain from strenuous exerci se (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each bloo d collection for clinical 
laborator y tests.  Walking at a normal pace will be permitted .

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 32In order to standardize the conditions on PK sampling day s, par ticipant s will be 
required to refrain from ly ing down (except when required for BP, pulse rate , and 
ECG measurements), eating, and drinking beverages other than water during the first 
4 hours after dosing.
Participant s will be confined to the procedure roo m for the first 4 hours after dosing 
on Day 1during continuous cardiac monitoring, except to use the bathroom.  After 
this, if the equipme nt setup allows, participant s may  be ambulatory  during the ECG 
monitoring period, but should not engage in strenuous activities.  If equipment does 
not allow ambulation, appropriate accommodations will be made by  the investigator 
site to facilitate continu ous monitoring (eg, bedside urinals should be provided to 
accommodate 
participant s’ excretory  needs) .
Participants wi ll be advised to avoid direct sunlight exposure or any  high intensity  
UV light exposure, from admission in Period 1 through the follow -up c ontact. In 
addit ion, participants will be instructed to appl y sun cream/lotion with a sun 
protection factor (SPF) of
≥50, as appropriate.
5.3.4. Contraception
Contraception is only required for male stud y participants and is recommended for partners 
of male s tudy participants wh oare WOCBP.
The investigator or his or her designee, in consultation with the participant , will conf irm that 
the 
participant has sele cted an appropriate method of contraception for the individual 
participant and his or her partner(s) f romthe permitted lis t of contraception methods (see 
Appendix 4 Section 10.4.4 )and will confirm that the participant has been instructed in its
consiste nt and corr ect use.  At time points indicated in the schedule of activities ( S oA), the 
investigator or d esignee will inform the participant of the need to use highly  effective 
contraception consistently and correctl y and d ocument the conversa tion and the participant ’s 
affirmation in the participant ’s chart ( participant s need to affirm their consistent and co rrect 
use of at least 1 of the sele cted methods of contraception).  In addition, the investigator or 
designee will ins truct the participan tto call immediately  if the selected contraception method 
is discontinued or if pregnancy  is known o r suspected in the participant or partner.
5.4.Screen Fa ilures
Screen failures are defined as participants who consent to participate in th e clinical study  but
are not subsequently  randomly  assigned to study  intervention /enrolled in the study . Screen 
failure data are collecte d and remain as source and are not reported to the clinical database.
Individuals who do not meet the criteria for par ticipation in this study  (screen failure) may  
not be rescreened. 

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 336.STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product( s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a s tudy 
participan t according to the study  protocol.
For the purposes of this protocol, study  intervention refers to all of the followin
g:
PF-07258669;
Placebo for 
PF-07258669 .
6.1.Study Intervention(s) Administered
PF-07258669 and placebo will be provided b y Pfizer as bulk pow ders for extemporaneous 
preparation of oral solutions and suspensions at the CRU.
PF-07258669 and pla cebo will be prese nted to the participant s in individual dosing 
containers.
6.1.1. Administration
Following an overnight fast of at least 10 h ours, parti cipants w ill receive study  intervention 
at approximately  0800 hours (plus or minus 2 hours) without breakfast on Day  1.
Investigator site personnel will administer a single oral dose of study  intervention on Day 1 
of each period with ambient temperature water to a total volume of approximately  240 mL. 
Study intervention will be administered according to th e EDR.
6.2.Preparation/Handlin g/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintai ned durin g transi t for all study  intervention sreceived and an y 
discrepancies are reported and resolved before use of the study  intervent ion. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supp ly or admini ster stu dy intervention.   All study 
interventions must be stored in a secure, environmentally  controll ed, and monitored 
(manual 
or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigat or and authorized si te staff.  At a 
minimum, daily  minimum and maximum temperatures for all site storage locations
must b e documented and av ailable upon request.  Data for nonworking days must 
indicate the minimum and maximum temperature ssince previousl y documen ted for 
all site storage locations upon return to business.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 343.Any excursions from the study  intervention label stora ge conditions shoul d be 
reported to Pfizer upon discovery  along with an y actions taken.  The site should 
activel y pursue options for re turning the study  intervention to the storage conditions 
described in the labeling, as soon as possible.  Once an excursion is identified, t he 
study  intervention must be quarantined and not used until Pfizer provides permission 
to use the study interventio n. Specific details regarding the definition of an excursion 
and information the site should report for each excursion w ill be provided to the site 
in the CRU site procedures.
4.Any storage conditions stated in the SRSD will be superseded by  the storage 
conditions stated on th e label.
5.Study  interventions should be stored in their original containers.
6.See the EDR for storage c onditions of the st udy intervention once prepared .
7. The investigator, institution, or the head of the medical institution (where applica ble) 
isresponsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconcili ation, and final di sposition records) , such as the 
IPAL or sponsor -approved equivalent .All study  intervention s will be accounted for 
using a study interv ention accountabilit y form/record.
8.Further guidance and information for the final disposit ion of unus ed study  
interventi ons are provided in the CRU site procedures.  All destruction must be 
adequatel y documented .  If destruction is auth orized to take place at the investigator 
site, the investigator must ensure that the materials are destro yed in complianc e with 
applicable e nvironmental regulations, institutional policy , and any  special instructions 
provided b y Pfizer.
Upon identification ofa produc t compla int, notify the sponsor w ithin 1 business day  of 
discovery .
6.2.1. Preparation and Dispensing
Within this pr otocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dis pensing to the participant by qualified 
staff.  Dispensing is defined as the provision of study  intervention , concomitant treatments, 
and ac compan ying information by  qualified staff member(s) to a healthcare provider, 
participant in accordance with this pr otocol.  Local healt h authority  regulations or 
investigator site guidelines may  use alternative terms for these activitie s.
PF-07258669 and placebo oral dosing solutions and suspensions will be prepared in the CRU 
by 2operators, 1 of whom is a pharmacist.   Details of dose pr eparat ion will be given in a 
separate EDR.  Prepared doses will be provided in unit dose containers a nd labeled in 
accor dance with Pfizer regulations and the investigator site’s labeling requirements.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 356.3. Measures to Minimize Bias: Randomiz ation and Blinding
6.3.1. Allocation to Study I ntervention
The investigator will assign participant numbers to the 
participant s as they  are screene d for 
the study .  Pfizer will provide a randomization schedule to the investigator and, in 
accordance with the rando mization num bers, t he participant will receive the study  treatment 
regimen assigned to the corresponding randomization nu mber.
Participants will be randomly  assigned to receive study  intervention from a central 
randomization scheme.   Investigators and part icipant
s will remai nblinded to each 
participant’s assigned study  intervention throughout the course of the stud y. In order to 
maintain thi s blind, an otherwise uninvolved third party  (for example, pharmacist) will be 
responsible for the preparation and d ispensing of all st udy intervention according to the 
randomization schedule and assigned treatment for the individual par ticipant .
6.3.2. Breaking 
the Blind
The method for breaking the blind in this study  will be manual.  In case of an emergency , the 
investigator has the sole responsibility  for determining if unblinding of a participant’s 
treatment assignment is warranted. Partici pant safety  must al ways be the first consideration 
in making such a determination.  If the investigator decides that unblinding is warr anted, the 
investiga tor should make every  effort to contact the sponsor prior to unblinding a 
participant’s treatment ass
ignment unless this could delay  further manag ement of the 
participant. If a participant’s treatment assignment is unblinded, the spons or must be notified 
within 24 hours after breaking the blind. When the blinding code is broken, the reason must 
be fully documented inthe CRF.
Blood specimens will be obtained from all participants for PK anal ysis to maintain the study  
blind at the inves tigatorsite.  Only  the investigator site staff and blinded study  monitor, if 
assigned, will be blinded to study  treatmen
t.  A limited numbe r of Pfizer study  team 
personnel will be unblinded to participant treatments in order to permit real -time 
interpreta tion ofthesafety  and PK data and provide information necessary  to potentially  alter 
the dose -escalation sequence.  The blinded study  monit or, if assigned, will remain blinded to 
treatment until all monitoring for the stud y has been completed.  Specimens from pa rticipants 
randomized to placebo will not be routinely  anal yzed.  To minimize the potential for bias, 
treatment ra ndomization informa tion will be kept confidential b y Pfizer unblinded personnel 
and will not be released to the blinded investigator or bl inded in vestigator site personnel until 
the study  database has been locked or the investigator requests unblinding for safety  reasons.
6.4.Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  fromthe
investigator or designee, under medical supervision.  The date and time of each dose 
administered in the clinic w ill be recorded in the source documents and recorded in the 
CRF .  
The dose of stud y intervention and study participant identification w illbe confirmed at the 
time of dosing b y a member of the stud y site staff .

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 366.5. Concomitant Therapy
Use of prescription or nonprescription dru gs and dietary  and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to th e firstdose of study 
intervention through the follow -up contact .  Limited use of nonprescription medications that 
are no t believed to affec t participant safety  or the overall results of the study may  be 
permitted on a case -by-case basis following approval bythesponsor .  
Acetaminophen/paracetamol may  be used at doses of ≤
1g/day .
Females taking hormone replacement therap y may be eligible to participate in this study  if 
they are willing to discontinue therapy  at least 28 days prior to the first dose of study  
treatment and remain off hormonal therap y for the duration of the study .
All concomitant treatments taken during the s tudy must be recorded with indication, daily  
dose, and start and stop dates of administration.  All participant s will be questioned about 
conco mitant treatment at each clinic visit.
Treatments taken with in 28 days before the first dose of study  interventio n will be 
documented as a prior treatment.  Treatments taken after the first dose of study  intervention
will be documented as concomitant treat ments.
6.5.1. Rescue Medic ine
There is no rescue therapy to reverse the AEs observed with PF-07258669; standard medical 
supportive care must be provided to manage the AEs. 
6.6.
Dose Modification
The decision to proceed to the next dose level of PF-07258669 (eg, an increase, decrease, or 
repeat of a previous dose level) will be made b y the study  team and the investigator based on 
safet y, tolerabilit y, and preliminary
 PKdata at the prior dose level. At least 6 participants 
(including at least 1 placebo participant) mu st complete the prior dose level. PK data through 
at least 24 hours post -dose will be reviewed.
The dosing sche dule may also be adjusted to add cohorts (8 participants/cohort) to evaluate 
additional dose levels. The study  procedures for these 
additional participant(s)/cohort(s) will 
be the same as that described for other stud y participants/cohorts.
6.6.1. Dose Escalation and Stopping Rules
Precautionary  sentinel dosing will be used in each period of each cohort. Two participants 
(1receiving PF -07258669 and 1 receiving placebo) within a period will be dosed initially  
before the remaining participants of that period are dosed. Safet y and tolerability  data 
through at least 24 hours post -
dose for the sentinel participants will be reviewed prior to 
dosing the remaining participants of that period.

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 37Dose escalation stopping rules will be used to determine whether the maximal tolerated dose 
has been attained.  Dose escalation may be stopped if it is determined that the limits of safety and/or tolerability have been reached.  This decision will be made after a discussion takesplace between the sponsor study team and the investigator.  The sponsor study team may not overrule the investigator’s decision to stop dose escalation.  If dose escalation is stopped because of any of these criteria, additional cohorts may receive the same or lower doses of the study intervention.
The dose escalation will be terminated based on the following criteria:
•If 50% or more of the participants receiving active drug at a given dose level (but not 
participants receiving placebo) develop similar clinically significant laboratory, ECG, or vital sign abnormalities, in the same organ class, indicating dose-limiting intolerance.
•Severe nonserious AEs, considered as, at least, possibly related to study intervention
administration, in 2 participants at a given dose level (but not participants receiving placebo), independent of within or not within the same system organ class, indicating dose-limiting intolerance.
•Dosing will be paused for any SAE that occurs in a participant receiving active 
treatment until causality is fully assessed by the PI and sponsor.  Dosing may resume if the SAE is determined to be not drug-related by the PI and sponsor.  If the SAE is determined to be either drug-related or unknown, either dosing will cease or the SAE will be evaluated by the sponsor’s protocol review committee (or similar review group), which is independent of the study team and investigators.  If the protocol review committee determines that dosing may resume, a plan that mitigates risks to participants with the resumption of dosing will be implemented.  Such a plan could include a revision of inclusion/exclusion criteria, repeating or reducing the dose, or adding appropriate safety monitoring.
•It is determined that the limit of safety and/or tolerability has been reached.  This 
decision will be made following discussions between the study team and the investigator.
•Other findings that, at the discretion of the study team and investigator, indicate that 
dose escalation should be halted.
•  
•If, based on the observed data, the group mean C
maxor AUC (based on total plasma 
concentration) of the next planned dose is projected to exceed the escalation limits, that dose will not be explored.  Modified doses may be explored if they are not expected to exceed PK stopping criteria.CCI
PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 38Progression to the next dose level will occur if the last dose was well tolerated and after 
satisfactory  review of the available safet y and PK data.
At a minimum, review of safet y and tolerability data through 48 hours post- dose, and PK 
data through 24 hours post -dose, isrequired in order to escalate to the next dose level. The 
safet y and tolerab
ility assessment s are outlined in the study  endpoints a nd include assessment 
of adverse events, clinical safet y laboratory
 tests, vital signs, continuous cardi acmonitoring, 
12-lead electrocardiograms, respiratory  rate, oral body  temperature, phy sical exam i nations, 
and ne urological examinations.
6.7.Intervention 
After the End of the Study
No intervention will be provided to study  participants at the end of the stud y.
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Inter vention
In rare instances, it may  be ne cessary  for a participant to permanentl y discontinue study  
intervention (definitive discontinuation) .
Reasons for definitive discontinuation of study  
intervention include the following : adverse event, or some other (administrative) reason.
If study  interv ention is definitively  discontinued, the participant will not remain in the study  
for further evalu ation. See the SoA for data to be collected at the time of discontinuation o f
study  intervention.
In the event of discontinuation o f study  intervention, it must be documented on the 
appropriate CRF/in the medical records whether the pa rticipant is discontinuing further 
receipt of stud y intervention or also from study  procedures, p osttreatmen t study  follow - up, 
and/or future collection of additional information.
ECG Changes
A participant who meets either of the following bulleted criteria based on the average of 
triplicate ECG readings will be withdrawn from the study intervention . 
Q
TcF >500 msec.
Change from baseline: QTcF >60 msec.
Ifa clinically  significant finding is identified (including, but not limited to ,changes from 
baseline i nQTcFafter enrollment ), the investigator or qualified designee will determine if 
the participant can continue in the study  and if any change in partici pant management is 
needed. This review of the ECG printed at the time of collection must be documented . Any 
new clinicall y relevant finding should be reported as an AE.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 39Potential Cases of Acute Kidne yInjury
Abnormal values in SCr concurrent with presenc e or absence of increase in BUN that meet 
the criteria below, in the absence of other causes of kidney  injury, are considered potential 
cases of acute kidney  injury  and should be considered important m e
dical events. 
An increase of 
≥0.3 mg/dL (or ≥26.5 µ mol/L) in SCr level relative to the participant’s own 
baseline measurement should trigger another assessm ent of SCr as soon as practicall y 
feasible, preferabl y within 48 hours from awareness.
If the seco nd assessment (after the first observations of ≥ 0.3mg/dL [or ≥26.5 µ mol/L ]in SCr
relative to the participant’s own baseline measurement) is ≥0.4 mg/dL (or ≥35.4 µ mol/L ), the 
participant should be discontinued from the stud
y and adequate, immediate, suppo rtive 
measures taken to correct apparent acute kidney  injury .
Participants should return to the investigator site and be evaluated as soon as possible, 
prefer ably within 48 hours from awareness of the second assessment confirming abnormal 
SCr result.  This evaluation should include labo ratory  tests, detailed history, and phy sical 
assessment.  In addition to repeating SCr, laboratory tests should include serum B UN, serum 
creatine kinase, and serum electrol ytes (including at a minimum potassium, sodium, 
phospha te/phosphorus, and calcium), in addition to urinary  dipstick, urine microscopic 
examination, and urinary indices.  All cases confirmed on repeat testing as m eeting the 
laboratory  criteria for acute kidney  injury , with no other cause(s) of laboratory  abno r
malities 
identified, should be considered potential cases of drug- induced kidney  injury  irrespective of 
availability  of all the results of the investigations performed to determine etiology  of the 
abnormal SCr.  If ≥2 healthy  participants in a given period are noted to have 2 consecuti ve
SCr results of ≥0.3 mg/dL (or ≥26.5 µ mol/L ), an assessment of whether the finding may  be 
considered an adverse drug reaction should be undertaken.
7.2.Participant Discontinuation/ Withdra walFrom the Study
A participant may  withdraw from the study  at an y time at his/her own request.  Reasons for 
discontinuation from the study  include the following:
Refused further follow -up;
Lost t ofollow-up;
Death ;
Study  terminated by  sponsor ;
Discretio
n of the investigator or sponsor for safety or behavioral reasons, or the 
inability  of the participant to comply  with the protocol required schedule of study  
visits or procedures.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 40At the time of discont inuing from the stud y, if possible, an earl y discontin uation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
The early  discontinuation visit applies only  to participants who are enrolled/ randomized and 
received at least 1 dose of the study  intervention and then are prematurely  withdrawn from 
the study .  Participants should be questioned regarding their reason for withdrawal.
The participant will be per manentl y discontinued both from the study intervention and from 
the stu
dy at that time.
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not te sted,and t he investigator must document any  such req uests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future informatio n, no further evaluations should be performed and no 
additional data should be collected.  The sponsor may  retain and continue to use any  data 
collected before such withdrawal of consent.
Lack of co
mpletion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant ’s safet y was preserved.
7.2.1. Withdrawal of Consent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be f ollowed 
for protocol -specified follow -up procedures.  The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
with him or her or persons previously  authorized by the participant to provide this 
information.  Particip ants should notify  the investigator in writing of the decision to 
withdraw consent from future follow- up, whenever possible.  The withdrawal of consent 
should be explained in detail in the medical r ecords by  the investigator, as to whether the 
withdrawal i s only  from further receipt of study  intervention or also from study  procedures 
and/or posttreatment study  follow -up, and entered on the appropriate CRF page.  In the event 
that vital stat us (whethe rthe participant is alive or dead) is being measu red, publicly  
available information should be used to determine vital status only  as appropriately  directed 
in accordance with local law.
7.3.Lost to Follow -up 
A participant will be considered lost t o follow -upif he or she repeatedl y fails to return for 
scheduled vi sits and is unable to be contacted b y the study  site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 41The site must attempt t o contact the participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether or not the participant wishes to and/or 
should continue in the stud y.
Before aparticipant is deemed lost to follow -up, the investigato r or designee must 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participa nt’s last known mailing
address o rlocal equivalent methods). These contact attempts should be documented 
in the participant’s medical record .
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND P ROCEDURES
The investigator (or an appropriate delegate at the invest igator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.  
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety  issues should b e discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the study  design r equirement s, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The inve stigator will maintain a screening log to 
record details of all pa rticipants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Participants will be screened within 28 days prior to administration of the study  inter vention 
to confirm that they  meet the study  population criteria fo r the study .  If the time between 
screening and dosing exceeds 28 days as a result of unexpected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the labor atory  results obtained prior 
to first dose administration meet eli gibility  criteria.
A participant who qualified for thi s protocol but did not enroll from an earlier cohort/group 
may be used in a subsequent cohort/group without rescreening, provided labora tory results 
obtained prior to the first dose administration meet eligibility  criteria for this study .  In 
addition, oth
er clinical assessments or specimen collections, eg, banked biospecimens, may  
be used without repeat collection, as appropriate.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 42Every  effort should be made to ensure that protocol -required tests and pr ocedures are 
completed as described.  However, it is a nticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perf orm 
the test.  I n these cases, the investigator must take all step s necessary  to ensure the safet y and 
well-being of the participant.  When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y correcti ve and preventive 
actions that he or she has taken to ensu
re that required processes are adhered to as soon as 
possible.  The study  team must be informed of these incidents in a timely  manner.
Ifan IV catheter is utilized for blood sample collecti ons, ECG s
and vital sign assessments 
(pulse rate andBP) should be collected prior to the insertion of the catheter .
Forsamples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will b e provide d to the investigator site prior 
to initiation of the study .
The total blood sampling volume for individual par ticipant s in this study  is approximately  
475mL. The actual collection times of blood sampling may  change. Additional blood 
samples may  betak en for safet y assessments at times specified b y Pfizer, provided the total 
volume taken during the study  does not exceed 550 mL during an y period of 60 consecutive 
days.
To prepare for stud y participation, participant s will be instructed on the infor mationin the 
Lifesty le Considerati onsand Concomitant Therapy sections of the protocol.
8.1.Efficacy Assessments
No efficac y assessments are being conducted in this study .
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA .  Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
8.2.1. Physical Examinations
A complete physical examina tionwill include , at a minimum, head, ears, eyes , nose, mo
uth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, assessments of genera l appearance, 
the respiratory  and cardiovascular systems, a nd participant -reported s ymptoms.
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation. 

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 43Height a nd we ight will also be measured and recorded as per the SoA.  For measuring 
weight, a scale with appropriate range and resolution is used and must be placed on a stable, 
flat surface.  Participant s must remove shoes, bulky  layers o f clothing, and jackets so that 
only light clothin g remains .  They  must also remove the contents of their pockets and remain 
still during measurement of weight. 
8.2.2. Neurological Examinations
Neurological examinations may  be conducted b y a phy sician, trained phy sician's assistant, or 
nurse pra ctitioner as acc eptable a ccording to local regulation. The neurological exam will 
consist of assessment of higher cortical function, the cranial nerves, motor function, deep 
tendon reflexes, sensory  exam, and coordination andgait. The exam should be done 
to the 
extent ne eded to assess the participant for any  potential changes in neurological status, as 
determined b y the investigator (or designee).
8.2.3. Vital Signs
Supine BP will be measured with the participant’s arm supporte d atthe level of the heart, and 
recorded to the nea rest mm Hgafter approximately  5minutes of rest.  The same arm 
(preferabl y the dominant arm) will be used throughout the study.  Participant s should be 
instructed not to speak during measu rements.  
The same properl y sized and calibrated BP cuff will be u sed to 
measure BP each time.  The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial a rtery  for at le ast 
30seconds.  When the timing of these measuremen ts coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times, o f BP and pulse rate will be 
permitted, as necessary , to ensure appr opriate collection of safety  data.
The procedure for collecting postural or orthostatic data will be:
Assess BP after the participant is in the supine position for a minimum of 5 minutes;
Have the partici pant stand up for 2 minutes;
Assess BP after the participan t is in the standing position for approximately  
2minutes.
Orthostatic hy potension is defined as a decrease of ≥20 mmHg for s ystolic BP or 
≥10mmHg for diastolic BP 2 minutes after standing from a supine position.  Orthostatic 
hypotension may  be symptomatic or as ymptomatic.  Sy mptoms of orthostatic hy potension 
are those that develop upon assuming the erect postur e from a supine position and may  
include: lightheadedness, dizziness, b lurred vision, weakness, fatigue, cognitive impairment, 
nausea, palpitations, tremulousness, headache, and/or neck ache.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 44If a participant has s ymptoms suggestive of orthostasis, but not documented orthostatic 
hypotension, repeated measurements of supine/st anding BP (triplicate supine/1 standing and 
further monitoring based on investigator/medical judgement) should be obtained. Lesser 
degrees of BP reduction may  still be considered clini cally significant if the participant 
becomes s ymptomatic upon standing, especiall y in the presence of a significant increase 
inpulse rate ( ≥30 beats per minute [bpm]).
8.2.4. Respiratory Rate
Respiratory  rate will be measured at times specified in the SoA. After approximately  
5minutes rest in supine position, respiratory  rate will be measured b y observing and 
counting the respirations of the subject for 30 seconds and multiplied by  2. When blood 
pressure is to be taken at the same time , respiration measurement will be done during the 
5minutes of rest and before blood pressure measu rement.
8.2.5. Oral Body Temperature
Body temperature will be measured orally. No eating or drinking is allowed for 15 minutes 
prior to the measurement.
8.2.6. Electrocar diograms
Standard 12-l ead ECG s utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and me asures PR, QT, and QTc Finterv alsand QRS 
complex .Alternative l ead placement methodology  using torso leads (eg ,Mason- Likar) is not 
permitted given the potential risk of discrepancies with ECGs acquired using standard limb 
lead placement.  All scheduled ECGs should be performed after the participant has rested 
quietly for at least 10 minutes in a supine position. 
Triplicate 12 -lead ECGs will be obtained approximately  2 to 4 minutes apart; the average of 
the triplicate ECG measurements collected before dose administration on Day 1 of each 
period will serve as each participant ’s baseline QTc Fvalue. 
To ensure safet y of the participant s, a qualified individual at the investigator site will make 
comparisons to baseline measurements.   Additional ECG monitorin g will occur if a) the 
mean va lue from the triplicate measurement s for any  postdose QTc Finterval is increased by  
≥
60msecfrom the baseline andis >450 msec ; or b) an absolute QTc Fvalue is ≥500 msec
for an y scheduled ECG.  If either of these conditions o ccurs, then a single ECG measu rement 
must be repeated at least hourly  until QTc Fvalues from 2 successive ECGs fall below the 
threshold value that triggered the repeat measurement .

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 45If a) a postdose QTc Finterval remains ≥60 ms ecfrom the baseline andis >450 msec; or 
b) an absolute QTcF value is ≥500 msecfor an y scheduled ECG for greater than 4 hours (or 
sooner, at the discretion of the investigator) ;or c) QTcFintervals get progressively longer, 
the participant should under go continuous ECG monitoring.  A cardiologist should be 
consu lted if QTc F intervals do not return to less than the criterion listed above after 8 hours 
of monitoring (or sooner, at the discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement a s contributing to the ECG abnormality .  It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings.  If a machine -read 
QTcFvalue is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTc
Fvalues are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7.
8.2.6.1. Continuous Cardiac Monitoring by Telemetry
All abnormal rh ythms will be recorded and reviewed by  the study  physician for the presence 
of rh ythms of potential clinical concern.  The time, duration, and description of the clinicall y 
significant event will be recorded i n the CRF.  In addition, a prin ted record of the tracing(s) 
of the clinicall y significant rhythm(s) will be made and retained with other source 
documents.
Telemetry  should be collected using a centralized sy stem that also allows for the storage and 
advance d anal ysis of all recorded data in order to preserve important events for future 
evaluations.  Holter monitoring should not be used in parallel with continuous telemetry , 
unless it is the only  means of data storage available at the investigator site, or ve rifiable 
arrhythmia quantificat ion is required.  To establish a baseline, telemetry  should be recorded 
for at least 2 hours before dosing in Period 1.  This may  be done immediately  prior to dosing 
or at some 2- hour continuous interval in the 24 hours prior to dosing, as long as the reco rding 
is performed when the participant is awake.  Telemetry  may  be stopped within a reasonabl y 
short period of time prior to dosing, in order to avoid interfe rence with study  operations 
conducted immediatel y before dosing.  However, it is expected that the telemetry leads will 
be in place and the s ystem connected prior to dosing.
8.2.7. Clinical Safety Laboratory Assessments
See Appendix 2 for the list of clinical safet y laboratory  tests to be performed and the SoAfor 
the timing and frequency.  All protocol -required laboratory  assessments, as defined in 
Appendix 2 , must be conducted in accordance with the laboratory  manual and the SoA. 
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y percei ved safet y issues.  

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 46The investigator must review the laboratory  report, document this review, and record a ny 
clinically  relevant changes occur ring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  the investigator to be more severe than expected for 
the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 14daysafter the last dose of stud y intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically  
significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
the investigator, the etiology  should be id
entified and the sponsor notified.
See Appendix 6for suggested actions and follow -up assessments in the event of potential 
drug-induced liver injury.
Participant s may  undergo random urine drug testing at the discret ion of the investigator.  
Drug testing conducted prior to dosing must be negative for participant s to receive study  
intervention . 
8.2.8. COVID -19 Specific Assessments
Participants will be tested for SARS -COVID -19 infection by  PCR prior to being admitted to 
the 
clinic. Subsequent COVID -19 test s wil l be performed ifthey develop COVID -19 like 
symptoms. Additional testing may  be required b y local regul ations or b y the investigator.
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3.
AEswill be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized representative).
The investigator and an y qualified designee s are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to ass ess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
thestudy  intervention (see Section 7.1). 
Each participant will be questioned about the occurrence of AEs in a nonleading man ner.
In addition, the inv estigator may  be requested by  Pfizer Safet y to obtain specific follow -up 
information in an expedited fashion.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 478.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collec tion 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or rece iving study  intervention ), through and including a 
minimum of 28 calendar days , except as indicated below, after the last admi nistration of the 
study  intervention .
Follow -up by  the investigator continues throughout and after the active collection period an d 
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the 
investigator and Pfizer concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant wi
thdraws from the study  and also withdraws consent for the collection of 
future information, the activ e collection period ends when consent is withdrawn.
If a participant definitively  discontinues or temporarily  discontinues study  intervention 
because of anAE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the CT SAE Report Form.
Investigators are not obligated to activel y seek AE or SAE after the participant has concluded 
study  participation . However, if the investigator le arns of any  SAE, including a death, at an y 
time after a participant has completed the study , and he/she considers the event to be 
reasonabl y related to the study  intervention, the investigator must promptl y report the SAE to 
Pfizer us ing the CT SAE Report Form.
8.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.1 are reported to Pfizer Safety  onthe CT SA E Report Form immediately upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24
hours of it bei ng available.
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.1 , will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly observed and all spontan eously  reported 
AEs and SAEs reported by  the participant.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 488.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/ or SAEs.
  Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabiliza tion, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independen t determination of 
possible causality .  An y information relevant to the event, such as concomit ant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possib le to Pfizer Sa fety. 
Further information on follow -up procedures is given in Appendix 3.
8.3.4.
Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of a nSAE is essential so t hat legal 
obligations and ethical responsibilities towards the safet y of participants and the sa fety of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and othe r 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Inves tigator safety reports must be prepared for SUSAR saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives SUSARs or other specific safety information (eg, summary or 
listing o f SAEs) from t he sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the stu dy interventio nunder stud y during pregnancy  or br eastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 498.3.5.1. Exposure During Pregnancy
An EDP occurs if: 
A male participant who is receiving or has disco ntinued study  intervention exposes a 
female partne r prior to or around the time of conception
.
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environm ental exposure during pregnancy : 
A female family member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  ingestion, inhalation, or skin 
contact .
A male famil y member or healthcare provider who has been exposed t o the study  
intervention by  ingesti on, inhalation, or skin contact then exposes his female 
partner prior to or around the time of conception .
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, 
irrespective of whether an S AE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator m ust report 
this information to Pfiz er Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until at least 
28days after the last dose of the stud y intervention.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to P fizer Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnanc y and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP S upplement al Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason( s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by  gross visual inspection (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings a re 
reported).

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 50Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy meets 
the crite ria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y [in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death]), the investigator sho uld follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
Pfizer Safety  as SAEs follows: 
Spontaneous abortion including miscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator asse sses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional informa tion regarding the EDP may  be requested by  the sponsor. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator wi ll provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The investigator must document in th e source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide t o his 
partner.
8.3.5.2. Exposure During Breastfeeding
An exposure during breastfeeding occurs if:
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of envi ronmental 
expos ure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed t o the study  intervention 
by inhalation or skin contact.  
The investigator must report exposure during breastfeeding to Pfizer Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred.  The 
information must be rep orted using the CT SAE Report Form.  When exposure during 
breastfeeding occurs in the setting of envir onmental exposu re, the exposure information does 
not pertain to the participant enrolled in the study , so the information is not recorded on a 
CRF. Howev er, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
An exposur e during breast feeding report is not created when a Pfizer drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in acc ord with 
authorized use.  However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 518.3.5.3. Occupational Exposure
An occupational exposure occurs when a person receives unplanned dir ect contact with the 
study  intervention , which may  or may  not lead to the occurrence of an AE. Such persons 
may include healthcare provider s, famil y members, and other roles that are involved in the 
trial participant’s care.
The investigator must report occupational exposure to Pfizer Safet y within 24 hours of the 
investigator’s awareness regardless of wh ether there is 
an associated SAE.  The information 
must be reported using the CT SAE Report Form.  Since the information doe s not pertain to a 
participant enrolled in the study , the information is not recorded on a CRF; however, a copy  
of the completed CT SAE Report Form is maintained in the investigator site file .
8.3.6. Cardiovascular and Death Events
Not applicable.
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.3.8. Adverse Events of Special Interest
Not applica ble.
8.3.8.1. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.
8.3.9. Medical Devic e Deficiencies
Not applicable.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by the wrong participant , or at the wrong time, at the wrong dosage strength , or 
inadvert exposure .
Exposures to the study  intervention under stud y may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on th e CT SAE Report 
Form to Pfizer Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 52Medication errors include:
•Medication errors involving participant exposure to the study intervention;
•Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours.Whether or not the medication error is accompanied by an AE, as determined by the 
investigator, the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE.
8.4. Treatment of Overdose
 
The sponsor does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1. Contact the medical monitor within 24 hours.2. Closely monitor the participant for any AEs/SAEs and laboratory abnormalities for at 
least 5 half-lives or 28 calendar days after the overdose of PF-07258669 (whichever is longer).   
3. Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF.
4. Overdose is reportable to Safety only when associated with an SAE.
5. Obtain a blood sample for PK analysis within 5 days from the date of the last dose of 
study intervention if requested by the medical monitor (determined on a case-by-case basis).
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the medical monitor based on the clinical evaluation of the participant.CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 CCI
CCI
CCI
CCI
CCI
CCI
CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 54 
 
 
 
 
 
 
 
 
 
 
 
 
8.7. Genetics
8.7.1. Specified GeneticsGenetics (specified analyses) are not evaluated in this study.
8.7.2. Banked Biospecimens for Genetics
A 2-mL blood sample optimized for DNA isolation Prep D1.5 will be collected as local 
regulations and IRBs/ECs allow.
Banked Biospecimens may be used for research related to the study intervention(s).  Genes 
and other analytes (eg, proteins, RNA, nondrug metabolites) may be studied using the banked samples. CCI
CCI
CCI
CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 55See Appendix 5 for information regarding genetic research.  Details on processes for 
collection and shipment of these samples can be found in the lab manual and other supporting documentation.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
CCI
CCI
CCI
CCI

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 568.8.2. Banked Biospecimens for Biomarkers
Additional Banked Biospecimens in this study  are:
10-mL whole blood (Prep B2 optimized for serum ) .
Banked Biospecimens will be collected as local regulations and IRB/ECs allow. Banked 
Biospecimens may  be used for research related to the study  intervention(s) and safet y 
biomarkers .Genes and other anal ytes (eg, proteins, RNA, nondrug metabolites) may  be 
studied using the banked samples. See Appendix 5 for information regarding geneti c 
research.  Details on processes for collection and shipment of these samples can be found in 
the lab manual and other suppor ting documentation. 
8.8.3. Specified Gene Expression (RNA) Research
Specified gene expression (RNA) research is not included in this stu dy.
8.8.4. Specified Protein Research
Specified protein research is not included in this study .
8.8.5. Specified Metabolomic Research 
Speci fied metabolomic research is not included in this study .
8.9.Immunogenicity Assessments
Immunogenicit y assessments are not included in this study .
8.10. Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
9.STATISTICAL CONSIDER
ATIONS 
Detailed methodology  for summary  and stati stical anal yses of the data collected in this study  
is outlined here and further detailed in a SAP, which will be maintained b y the sponsor. The 
SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses wi ll also be ref lected in a 
protocol amendment.
9.1.Statistical Hypotheses
No formal h ypothesis tests are planned for this study .

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 579.2.Sample Size Determination
A sample size of up to approximately  8participants per coho rt (approximately  6participants 
receiving PF-07258669 and up to 2participants receiving placebo within each period ) has 
been chosen based on the need to minimiz e first exposure to humans of a new chemical
entity  and the requirement to provide adequate sa fety, tolerability , and PK assessment at each 
dose level. There are 2
planned cohorts and an additional optional third cohort which will 
only be used if the objec tives of the study  are not fulfilled in Cohort 1 and Cohort 2.
Participants who discontinue prior to completion of the study  may  be replace d, at the 
discretion of the investigator and sponsor.
9.3.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis 
SetDescription
Enrolled /Randomly  
assigned to stud y 
intervention"Enrolled" means a participant's, or their legall y authorized 
representative’s, agreement to participate in a clinical study  
following completion of the informed consent process.  
Potential participants who are scr eened for the purpose of 
determining eligibility  for the study , but do not participate in 
the study , are not considered enrolled, unless otherwise 
specified b y the protocol.
Evaluable All participants randomly  assigned to study  intervention and 
who receiv ea dose of study  interventi on.
Safety All participants randomly  assigned to study  intervention and 
who receive a dose of study  intervention .  Participants will be 
analyzed according to the 
product they actuall y received.
PK Concentration All participants randomly  assigned to stud y intervention and 
who receive a dose of study  intervention and in whom at least 
1plasma concentration value is reported.
PK Parameter All participants randomly  assigned to study  intervention and 
who receive a dose of study  intervention and have at leas t 1 of 
the PK parameters of interest calculated .
9.4. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and pr ocedures for accounting for missing, unused, and spurious data. 
This sect ion is a summary of the planned statistical ana lyses of the primary  and secondary  
endpoints.  Analy sis of the tertiary /exploratory  endpoints will be documented in the SAP.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 589.4.1. Safety Analyses
All safet y anal yses will be performed on the safet y population.
AEs, ECGs, BP, pulse rate, respiratory  rate, oral b ody temperature, continuous cardiac 
monitoring, and safet y laboratory  data will be reviewed and summarized on an ongoing basis 
during the stud y to evaluate the safet y of participants.  Any clinical laboratory, ECG, BP, 
pulse rate , and respiratory  rate abno rmalities of potential clinical concern will be described.  
Safety  data will be presented in tabular and/or graphical format an d summarized 
descriptivel y, where appropriate.
Medical history , phy sical examinati on,and neurological examination information, a s 
applicable, collected during the course of the study will be considered source data and will 
not be required to be reported, unless otherwise noted.  However, an y untoward findings 
identified on phy sical and /or neurological examinations conducted during the active 
collection period will be captured as AEs, if those findings meet the definition of an AE.  
Data collected at screen ing that are used for inclusion/exclusion criteria, such as laboratory  
data, ECGs, and vital signs, will be considered source data, and will not be required to be 
reported, unless otherwise noted.  Demographic data collected at screening will be reported. 
In addition, selected screening laboratory  data may be reported.  
9.4.1.1. Electrocardiog ram Interval Analyses
Changes from baseline for the ECG parameters (ie, QT interval, heart rate, QTc Finterval, PR 
interval, and QRS complex )will be summarized by treatment and time.
The number (%) of participants with maximum postdose QTcF values and max imum 
increases from baseline in the following c ategories will be tabulated by  treatment: 
Safety QTc FAssessment
Degree of Prolongation Mild (msec) Moderate (msec) Severe (m sec)
Absolute value >450 -480 >480 -500 >500
Increase from baseline 30-60 >60
In addition, the number of participants with unc orrected QT values >500 msec will be 
summarized.
When more than 1 ECG is collected at a nominal time after dose administration (for example, 
triplicate ECGs), the mean of the replicate measurements will be use d to represent a single 
observation at that time point.  I f any  of the 3 individual ECG tracings has a QTc Fvalue 
>500 msec, but the mean of the triplicates is not >500 msec, the data from the participant’s 
individual tracing will be described in a safet y section of the CSR in order to place the 
>500 -msec value in appropriate clinical context.  However, v alues from individual tracings 
within triplicate measurements that are >500 msec will not be included in the categorical 
analysis unless the average from t he triplicate measurements is also >500 msec.  Changes 

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 59from baseline will be defined as the change between the postdose QTcF value and the 
average of the predose triplicate values on Day 1.  
In addition, an attempt may be made to explore and characterize the relationship between 
plasma concentration and QT interval length using a PK/PD modeling approach.  If a PK/PD relationship is found, the impact of participant factors (covariates) on the relationship may be examined.  The results of such analyses will not be included in the CSR.
9.4.2. PK Analyses
The analysis populations are defined as in Section 9.3 .
9.4.2.1. Derivation of PK Parameters
The PK parameters for PF-07258669, following oral dose administration, will be derived 
from the plasma concentration-time profiles as detailed in Table 2, as data permit. In all cases, actual PK sampling times will be used in the derivation of PK parameters.
Table 2. Plasma PK Parameters
Parameter Definition Method of Determination
AUC last Area under the plasma 
concentration-time profile from 
time 0 to the time of the last quantifiable concentration (C
last)Linear/Log trapezoidal method
AUC inf* Area under the plasma 
concentration-time profile from time 0 extrapolated to infinite timeAUC
last+ (C last*/k el), where C last* is the predicted 
plasma concentration at the last quantifiable timepoint estimated from the log-linear regression analysis
Cmax Maximum observed concentration Observed directly from data
Tmax Time for C max Observed directly from data as time of first occurrence
t1/2* Terminal half-life Log e(2)/k el, where k elis the terminal phase rate 
constant calculated by a linear regression of the log-linear concentration-time curve
•Only those data points judged to describe the 
terminal log-linear decline will be used in the regression
 
*As data permit.CCI

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 609.4.2.2. Statistical Methods for PK Data
Plasma concentrations of PF-07258669 will be summarized descriptively by dose and 
nominal PK sampling time.  Individual participant and median profiles of the plasma concentration-time data will be plotted by dose using actual (for individual) and nominal (for median) times respectively.  Median profiles will be presented on both linear and log scales.  
The plasma PK parameters will be summarized descriptively by dose in accordance with 
Pfizer data standards, as data permit.   
 
 
Additional PK analyses may be performed if deemed appropriate, and may not be included in 
the CSR.
9.4.3. Other Analyses 
Pharmacogenomic or biomarker data from Banked Biospecimens may be collected during or 
after the trial and retained for future analyses; the results of such analyses are not planned to be included in the CSR.
9.5. Interim Analyses
No formal interim analysis will be conducted for this study. As this is a sponsor-open study,
a limited number of the sponsor’s team members (excluding site staff) may conduct unblinded reviews of the data during the course of the study for the purpose of safety and tolerability assessments, facilitating dose-escalation decisions, facilitating PK modeling, and/or supporting clinical development. 
9.6. Data Monitoring Committee or Other Independent Oversight Committee
This study will not use a DMC. CCI
PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 6110. S UPPORTI NG DOCUMENTATION AND OPERATIONAL CONSIDE RATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and E thical Consid erations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICHGCP guidelines ;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol am endments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  the sponsor and submitted to an 
IRB/EC by  the i nvestigator and reviewed and approved by  the IRB/EC before the study  is 
initiated.
Any amendments to t he protocol will require IRB/EC approval before implementation of 
changes made to the study  design, except for changes necessary to eliminate an immediat e
hazard to study  participants.
The investigator will be responsible for the following:
Providing writt en summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
establishe d by the IRB/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
IRB/EC procedures
;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/2014 
for clinical studies (if a pplicable), and all other applicable local regulations .
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie , clinical hold) b y anapplicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of any  new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , Pfizer should be informed immed iately .  
In addition, the investigator will inform Pfizer immediat ely of any  urgent safet y measures 
taken b y the investigat or to protect the study  participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of ICH GCP that t he investigator becom
es aware 
of.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 6210.1.2. Financial Disclosure
Investigator s and subinvestigators will provide the sponsor with suff icient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The inves tigator or his/her re presentative will explain the nature of the st udy to the 
participant and answer all questions regarding the study .  The participant should be given 
sufficient time and opportunity  to ask questions and to decide whether or not to partic ipate in 
the trial.
P
articipants must be informed that their partic ipation is voluntary . Participants will be 
required to s ign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, HI PAA requirements, where applicable, an dthe IRB/EC 
or study  center.
The investigator must ensure that each study  participant is fully  informe d about the nature 
and objectives of the study, the sharing of data related to the study ,and possible risks 
associated with partici
pation, including the risks associated with the processing of the 
participant ’s personal data. 
The participant must be info rmed that his/her personal study -related data will be used by  the 
sponsor in accordance with local data protection law. The level o f disclosure must als obe 
explained to the participant.
The participant must be informed that his/her medical records may  beexamined by  Clinical 
Quality  Assurance auditors or other authorized personnel appointed by  the sponsor, by  
appropriate IRB/EC membe rs, and b y inspectors from regulatory  authorities.
The inves tigator further must ensure that each study  participant is fully informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
T
he medical record must include a statem ent that written informed consent was obtained 
before the partic ipant was enrolled in the study  and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the I C
D.
Participants must be reconsented to the most current version of the IC D(s) during their 
participati on in the study .
A cop y of the IC D(s) must be provided to the participant.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 63Unless prohibited by  local requirements or IRB/EC decision, the I CDwill conta in a separate 
section that addresses th e use of samples for optional additional research.  The optional
additional research does not require the collection of an y further samples. The investigator 
or authorized designee will explain t o each participant th eobjectives of the additional
research .Participants will be told that they  are free to refuse to par ticipate and may  
withdraw their consent at any  time and for any  reason during the storage period. A separate 
signature will be requ ired to document a pa rticipant's agreement to allow specimens to be 
used for additional research. Participants who decline to participate in this optional
additional research will not provide this separate signature .
10.1.4. Data Protection
All parties will compl y with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure p rotection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be passwor dprotected or secured in a loc ked room to ensure that only  
authorized study  staff have access.  The st udy site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the e vent of 
disaster.  In the event of a potential perso nal data breach, the study  site will be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required by  law.
To protect the rights and freedoms of part icipants with regard to the pro cessing of personal 
data, participants will be assigned a single, partic ipant- specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant name s will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by this single, participant- specific code. The study  site will 
maintain a confidential list of participant s who participated in the study , linking each 
participant ’s numerical code to his or her actual identity and medical record identification . In 
case of data transfer, the sponsor will protect the confidentiality  of participant
s’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.5. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly
 disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and oth er public registries in accordance with applicable local 
laws/regulations.  In addition, Pfizer report s study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported by Pfizer in an obje ctive, accurate, balanced, and 
complete manner and a re reported regardless of the outcome of the stud y or the country  in 
which the study  was conducted.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 64www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.go v for Pfizer -sponsore dinterventional 
studies (conducted in patients) tha t evaluate the safety  and/or efficacy  of a product,
regardless of the geographical location in which the study  is conducted.  These r esults are 
submitted for posting in accordance wit h the format and time lines set forth by  US law.
EudraCT
Pfizer posts clinical trial r esults on EudraCT for Pfizer -sponsored interventional studies in 
accordance with the format and timelines set forth by  EU requirements.
www.pfizer.com
Pfizer posts public disclosure s ynopses (C SR sy nopses in which any  data that could be used 
toidentify  individual participants have been removed ) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the corresponding study  results are
posted to www.c linicaltrials.gov.
Doc
uments within marketing authorization packages/subm issions
Pfizer complies with the European Union Pol icy 0070, the proactive publication of clinical 
data to the EMA website.   Clinical data, under Phase 1 of this policy ,includes clinical 
overviews, clini cal summaries, C SRs, and appendices containing the protocol and protocol 
amendments, sample CRF s, 
and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centrali zed procedure since 
01January 2015 and app lications for line extensions and for new indications submitted via 
the centralized procedure since 
01 July  2015.
Data Sharing
Pfize r provides researchers secure access to p atient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. Pfizer will make available data from th ese trials 
24months after study  completi on.  Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personall y identifiable information 
redacted.
Data requests are considered from qualified resear chers with the approp riate competencies t o 
perform the proposed analy ses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercia l/competitive or legal purposes.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 6510.1.6. Data Qual ity Assurance
All participant data relating to the stud y will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
respon sible for verify ing th at data entries are accurate and correct by  physically  or 
electronically  signing the CRF.
The investig ator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensu re that the CRFs are s ecurel y stored at the study site in encry pted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agen cy inspections and provide direct access to source data documents.   This 
verificat ion may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant personnel are available duri ng the monitoring visi ts and possible audi ts or 
inspections and that sufficient time is devoted to the process.
Monitoring d
etails describing strategy  (eg, risk- based initiatives in operations and quality  
such as risk management and mitigation strategies a nd analytical risk-based monitoring), 
methods, responsibilities ,and requirements, including handling of noncompliance issue s and 
monitoring techniques (central, remote, or on -site monitoring) ,are provided in the IQMP .
The sponsor or designee is responsib le for the data manage ment of this study ,including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  authorized site personnel are accurate, complete, and verifiable fro m source 
documents; that t he safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and document s, including signed IC Ds, pertaining to the conduct of this study  must 
be retained by the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No recor ds may  be destroy ed du ring
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or part y without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 66The investigator(s) will notify  the sponsor or its agents immediatel y of an y regulatory  
inspection notification in relation to the study .  Furthermore, the investigator w ill cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its a gent, whenever feasibl e, to be present during the inspection.  The 
investigator site and investigator will promptly  resolve any discrepancies that are identified 
between the stud y data and the participant's medical records.  The investigato r will promptly  
provide copies of the inspection findings to the sponsor or its agent.  Before response 
submission to the regulatory  authori ties, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such fin dings.
10.1.7. Source Document s
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected.   Source documents are filed at the investigator site.
Data reported on the CRF or entered i
n the eCRF that are from source docume nts must be 
consistent with the source documents or the discrepancies must be explained . The 
investig ator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Definitio n of what constitutes source data can be found in the Source Document L ocator .
Description of the use of computerized sy stem is documented in the Source Document 
Locator .
10.1.8. Study and Site Start and Closure
The study  start date is the da te on which the clinic al study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at an y 
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon 
study completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sp onsor if 
requested to do so b y the responsible IRB/EC or if such termination is required to protect the 
health of study  participants.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigat or to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guideli nes;

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 67Inadequate recrui tment of participants by  the investigator;
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulato ry authorities, and an y CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  the applicable regulatory  
requirements. The investigator shall promptly  inform the participant and should assure 
appropriate participant therapy  and/or follow - up.
Study termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the c ontract and this protocol ,the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may be published or prese nted at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  public ation in any  subsequen t publications 
such as secondary manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments and the investigator will, on request, remo ve an y previously  undisclosed 
confidential information before disclosure, except for an y stud y-or Pfi zer-intervention 
related information necessary  for the appropriate scientific presentation or understanding of 
the study  results.
For all publications rel
ating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publicat ions and authorship, including those established by  the 
International Committee of Medical Journal Editors.
The sponsor will comply  with the requirements for publication of the over all study  results 
covering all i nvestigator sites.   In accordance w ith stan dard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data.   In this case, a coordinating investigator will be designated by  mutual 
agreement.
Authorship of public ations for the overall study  results will be determined by  mutual 
agreement and in line with I nternational Committee of Medical Jour nal Editors authorship
requirements. 
If publication is addressed in the clinical study
 agreement, the publication policy  set out in 
this section will not apply.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 6810.1.10. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor's appropriately  qualified medical pers onnel for the 
study  is documented in the study  contact list located in the CTMS. 
To facilitate access to appropriatel y qualified medical personnel on stud y
-related medical 
questions or problems, participant s are provided with a conta ct card at the time of informed 
consent .  The contact card contains, at a minimum, protocol and study  intervention
identifie rs, participant numbers, contact information for the investigator site, and contact 
details for a contact center in the event that t he investigator site s
taff cannot be reached to 
provide advice on a medical question or problem origina ting from another hea lthcare 
professional not involved in the participant ’s participation in the study .  The contact number 
can also be used b y investiga tor staff if they  are seeking advice on medical questions or 
problems; however, it should be used only  in the event that the established communication 
pathway s between the investigator site and the study  team are not available.  I t is therefore 
intended to augment, but not repl
ace, the established communication pathway s between the 
investigator site and the study  team for advic e on medical questions or problems that may  
arise during the stud y.  For sites other than a Pfizer CRU, the contact number is not in tended 
for use b y the participant directly , and if a participant calls that number, he or she will be 
directed back to the investigator site.

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 6910.2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory results may be reported on these samples as a result of the method of analysis or the type of analyzer used by the clinical laboratory, or as derived from calculated values. These additional tests would not require additional collection of blood. Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.
Table 3. Protocol Required Safety Laboratory Assessments
Hematology Chemistry Urinalysis Other
Hemoglobin
HematocritRBC count
MCV
MCHMCHCPlatelet countWBC count
Total neutrophils (Abs)
Eosinophils (Abs)Monocytes (Abs)Basophils (Abs)Lymphocytes (Abs)BUN (urea) and 
creatinineeGFR (CKD-EPI)
Glucose (fasting)
CalciumSodiumPotassiumChloride
Total CO
2(bicarbonate)
AST, ALTTotal bilirubinAlkaline phosphataseUric acidAlbumin
Total protein
Lipid panel:
•Total cholesterol 
•Triglycerides
•HDL
•LDL (calculated)pH
Glucose (qual)Protein (qual)
Blood (qual)
KetonesNitritesLeukocyte esteraseUrobilinogen
Urine bilirubin
Microscopy
a•Urine drug screeningb
•COVID-19 testing
At screening only:
•FSHc
•Hepatitis B surface antigen
•Hepatitis B surface 
antibody
•Hepatitis B core antibody
•Hepatitis C antibody
•Human immunodeficiency 
virus
a. Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.b. The minimum requirement for drug screening includes cocaine, THC, opiates/opioids, benzodiazepines, 
and amphetamines (others are site and study specific).
c. For confirmation of postmeno
pausal status only.
Investigators must document their review of each laboratory safety report.
Laboratory/analyte results that could unblind the study will not be reported to investigator
sites or other blinded personnel until the study has been unblinded.
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may be retained and stored for the duration of the study.  
 CCI

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 7010.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, an d Reporting
10.3.1. Definition of AE
AE Definition
An AE is any untoward medical occurrence in a patient or clinical study 
participant, t emporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
NOTE: An AE ca n therefore be an y unf avorable and uni ntended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or e xacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory te st results (hematology , clinical chemistry , orurinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital s ign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgme nt of the investigator .Any abnormal laborato ry test 
results that meet any of the conditions below must be recorded as an A E:
Is associated with accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a cha nge in study  dosing (o utside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant addi tional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition including eithe r an 
increase in frequ ency  and/or intensity  ofthe condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a su spected drug -drug interaction.
Signs, sy mptoms , or the clinical sequelae of a suspected overdose of either study  
interventio n or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with po ssible 
suicidal/self -harming intent. Such ove rdoses should be reported regardless of 
sequelae.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 71Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with t he underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more seve re than expected for the 
participant’s conditi
on.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospita l).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, h ospitalization for signs/sy mptoms of the disease under study , death 
due to pro gression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “life-threat ening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the even t. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requi res inpatient hospital ization or prolongation of existing hospitalization
In general, hospitalization signifies that the par ticipant has been detained (usually  
involving at least an overnight stay ) at the hospital or emergency  ward for observation 
and/or t reatment that would no t have been appropriate in the phy sician’s office or
outpatient setting. Complications that occur dur ing hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as t o whether “hospitalization” occurred or was necessar y, the AE 
should be considered serious.
Hospitaliz ation for elective treatment of a preexisting condition that did not worsen from 

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 72baseline is not considered an AE.
d.Results in persistent disability/incap acity
The term disabilit y means a substantial disrup tion of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated hea dache, nausea, vomitin g, diarrhea, 
influenza, and accidental trauma (eg, s prained ankle) which may interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific ju dgment should be exercis ed in deciding whether SAE 
reporting is appropriate in other situations such a s important medical events that 
may not be immediatel y life-threatening or result in death or hospitalization but 
may jeopardize the participant or may  require medical or surgica l intervention to 
prevent one of the other outcomes listed in the above defini tion. These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive t reatment 
in an emergen cy room or at home for a llergic bronchospasm, blood dy scrasias or 
convulsions that do not result in ho spitalization, or development of drug 
dependency  or drug abuse.
Suspected transmission via a Pfizer product of an infectious agent, pathogenic or 
non-path ogenic, is considered serious.  The event may  be suspected from clinical 
symptoms or laboratory  findin gs indicating an infection in a patient exposed to a 
Pfizer product.  The terms “suspected transmission” and “transmission” are 
considered s ynon ymous.  Th ese cases are consider edunexpected and handled as 
serious expedited cases by pharmacovigilance personnel.  Such cases are also 
considered for reporting as product defects, if appropriate.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 7310.3.3. Recording/Reporting and Follow -up of AE sand/or SAE s
AE and SAE R ecording /Reporting
The table below summarizes the requirements for recording adverse events on the CR F and 
for reporting serious adverse events on the CT SAE Report Form to Pfizer Safety .  These 
requirements are delineated for 3 t ypes of events: (1) SAEs; (2) nonserious AEs; and
(3)exposure to the study  intervention under stud y during pregnancy  or breast feeding, and 
occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs shou ld be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE infor mation.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastf eeding, and 
occupation al exposureAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding .
Occupational exposure is 
not recorded.All (and EDP supplemental 
form for EDP)  
Note: Include all SAEs 
associated with exposure 
during pregnancy  or
breastfeeding. Includ e all 
AEs/SAEs associate d with 
occupational exposure.
When an AE/SAE occurs, it is the responsibilit yof the investigator to review all 
documentation (eg, hospital progress notes, laboratory  reports, and diagnostic 
reports) related t o the event.
The inves tigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the inv estigator to send photocopies of the participant’s 
medical records to Pfizer Saf ety in lieu of completion of the CT SAE Report 
Form /AE/SAE CRF page.
There may be instances when copies of medical records for certain cases are 
requested b y Pfizer Safety .Inthis case, all participant identifiers, with the 
exception of the participant n umber, will be redacted on the copies of the medical 

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 74records before submission to Pfizer Safety .
The investigator will attempt to establish a diagnosis of the event based on si gns, 
symptoms, and/or other clinical information. Whenever possible, the diagno sis (not 
the individual signs/sy mptoms) will be docum ented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE re ported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  the participant, causing minimal 
discom fort and not interfering with every day activities.
Moderate: An event that causes sufficient discomfo rt and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is assessed
as severe should not be confused with a nSAE.  Severe is a category  utilized for 
rating the intensit y of an event; and bot hAEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definiti on of an SAE, NOT when i t is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relations hip convey s that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship c annot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl yingdisease(s), concomita nt therap y, and other 
risk factors, as well as the temporal relationship of the event to study  interv ention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in his/her ass essment.
Foreach AE/SAE, the investigator must document in the medical notes that he/she
has reviewed the AE/SAE and has provided an assessment of causality .

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 75There may  be situations in which an SAE has occurred and the in vestigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor .
The investigator may  change his/her opinion of causality  in light of follow -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting re quirements.
If the investigator does not know whether or not the study  interventi oncaused the 
event, then the event will be handled as “related to study  intervention ” for reporting 
purposes, as defined b y the sponsor .  In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator must record this causal 
relationship in the sourc e
documents and CRF, and report such an assessment in the 
dedicated section of the CT SAE Report Form and in accordance with the SAE 
reporting requirements .
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  the 
sponsor to elucidate the nature and/or ca usalit y of the AE or S AE as fully  as 
possible. This may include additional laboratory  tests or investigations, 
histopathol ogical examinations, or consultation with other healthcare providers .
If a participant dies during participation in the study or duri
ng a recognized 
follow -up period, the investig ator wi ll provide Pfizer Safet y with a cop y of any 
postmortem findings includi ng histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of rece ipt of the information.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 7610.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safe tyvia an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to Pfizer Safety will be the electronic 
data c ollection tool.
If the electronic s ystem is un available, then the site will use the paper SAE data 
collection tool ( see nex t section) in order to report the event within 24 hours.
The site will enter the SAE data into the elec tronic sy stem as soon as the data
become available.
After the stud y is compl eted at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, the nthe site can report this information on a paper SAE form (see 
next section) or to Pfizer Safety  by telephone.
SAE Reporting to Pf izer Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit th is information to Pfizer Safety .
In circumstances when the facsimile is not working , notification by  telephone is 
acceptable with a c opy of the CT SAE Report Form sent by  overnigh t mail or 
courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages w ithin the designated reporting 
time frames.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 7710.4. Appe ndix 4: Contraceptive Guidance
10.4.1. Male Participan t Reproductive Inclusion Criteria
Male participants are eligible to participat e if they  agree to the following requirements during 
the intervention period and f or at least 28daysafter the last dose of stud y intervention, which
corresponds to the time nee ded to eliminate reproductive safet y risk of the study  
intervention(s):
Refrain from donating sperm .
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their pre ferred and usual lifes
tyle (abstinent on a lon g-term and persistent basis) and 
agree to remain abstinent .
OR
Must agree to use a male condom when engaging in any  activity  that allows for 
passage of ejaculate to another person .
In addition to male condom u
se, a highl y effective method of contraception is 
recommended for WOCBP partners of male participants (refer to the list of highl y 
effective methods below in Section 10.4.4 ).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to partici pate if she is not a WOC BP (see definitions belo win 
Section 10.4.3. 
The investigator is responsible for review of med ical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman 
with an earl y und etected
pregnancy . 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausa l 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstr ual cycle cannot 
be confirmed before the first dose of study  intervention, ad ditional evaluation should be 
considered.
Women in the 
following categories are not considered WOCBP:
1.Premenopausal female with 1 of the following:
Documen ted h ysterectomy ;

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 78Docume nted bilateral salpingectomy ;
Documented bilateral oophorectom y.
For individu als with permanent infertility  due to an alternate medica l cause other 
than the above, (eg, mullerian agenesis, androgen insensitivity ), investigator 
discr etion should be applied t
odetermining stud y entry .
Note: Documentation for any  of the above categori es can come from the site 
personnel’s review of the parti cipant’s medical records, medical examination, or 
medical history  interview.  The method of docume ntation should be record ed in the 
participant’s medical record for the stud y.
2.Postmenopausal female .
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.  I n addition, a
High FSH level in the postmenopausal ran ge must be used to confi rma 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 
Female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highl y effective contr aception methods 
if they wish to continue their HRT during the study .  Otherwise, they  must 
discontin ue HRT to allow confirmation of postmenopausal status bef ore study  
enrollment.
10.4.4. Contraception Methods
The following contraception methods are tobe used by  women of childbe aring pot ential who 
are partners of male participants in this study :
Highly Effective Methods That Have Low User Dependency 
1. Implantable prog estogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine d evice.
3.Intrauterine horm one-relea sing s ystem.
4.Bilateral tubal occlusion.
5.Vasectomized partner.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 79Vasectomized partner is a highl y effective contraceptive method provide d that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed.  If not, a n additional highl y effective method of contracep tion 
should be used.  The spermatogenesis cy cle is approximately  90days.
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulatio n.
Oral;
Intravaginal;
Transderma l;
Injectable.
7.Progestogen -only hormone contraception associated with inhibition of ovulation.
Oral;
Injectable.
8.Sexual abstinence.
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining fro m heterosexual intercour se during the entire period of risk associated 
with the study  intervention.  The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participan t.
One of the following effective barrier methods must be used in additio n to the highl y 
effective methods listed above that are user dependent:
Male or female condom with or without spermicide;
Cervical cap, diaphragm, or sponge with spermicide;
A combina tion of male condom with either c ervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 8010.5. Appendix 5: Genetics
Use/Analysis of DNA
Genetic variati on may  impact a participant’s response to study  intervention, 
susceptibility  to, and severi ty and progression of di sease. Therefore, where local 
regulations and IRB s/ECsallow, a blood sample will be collected for DNA anal ysis.
The scope of the genetic re search may  benarrow ( (eg, 1or more candidate genes ) or
broad (eg,the entire genome ),as appropriate to the scien tific que stion under 
investigat ion.
The samples may  be analy zed as part of a multistudy  assessment of genetic factors 
involved in the respons e to PF-07258669/placebo or study  interventions of this class 
to understand treatments for the disease(s) under stu dy or the disease(s) themselves .
The results of genetic analy ses may  be reported in the CSR or in a separate study  
summary , or may  be used for internal decision making without being included in a 
study  report.
The sponsor will store the DNA samples in a se cure sto
rage space with adequat e 
measures to protect confidentiality . 
The samples will be retained as indicated:
Samples for banking will be stored indefinitel y or for an other period as per local 
requirements.  
Participant s may  withdraw their consent for the stor age and/or use of their Banked 
Biospecimens at any  time by  making a request to the investigator; in this case, any  
remaining materia l will be destroy ed.  Data already  generated from the samples will 
be retained to p rotect t he integrit y of existing analyse s.  
Banked Biospecimens will be labeled with a code.  The key  between the code and the 
participant ’s personally  identify ing informat ion (eg ,name, address) will be held at the 
study  site and will not be provided to 
the sample bank.

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 8110.6. Appendix 6: Liver Saf ety: Suggested Actions and Follow -up Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no si gn of liver injury (as determined by  elevations in 
transaminases ) are termed “tolerators,” while those who show tr ansient l iver injury , but adapt 
are termed “adaptors.”  In some participant s, transaminase elevations are a harbinger of a 
more serious potent ial outcome.  These participant s fail to adapt and therefore are
"susceptible" to progressive and serious liver in jury, commonl y referred to as DILI.  
Participant s who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  todetermine if they  are an “adaptor” or are “susceptible.”
In the majority of DILI cases, e levations in AST and/or ALT prece de TBili elevations 
(>2×ULN) b y several day s or weeks.  The increase in TBili ty pically  occu rs while 
AST/AL T is/are still elevated above 3 ×ULN (ie, AST/AL T and TBili values will be 
elevated within the same lab oratory sample).  In rare instance s, by  thetime TBili elevations 
are detected, AST/ALT values might have decreased.  This occurrence is still regarded as a 
potential DILI.  Th erefore, abnormal elevations in either AST OR ALT in addition to TBili 
that meet the crite ria outlined below are c onsidered potential DILI (assessed per Hy ’s law 
criteria) cases and should alway s be considered importa nt medical events, even before all 
other possible causes of liver injury  have been excluded.
The threshold of laboratory  abnormal ities for a potential DI LI case d epends on the 
participant ’s individual baseline values and underly ing conditions.  Participant s who present 
with the following labora tory abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to defin itively  determine the et
iology  ofthe abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphat ase value
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values a re used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whicheve r is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased f rom 
baseline value b y anamount o fat least 1 × ULN or if the value reaches 
>3×ULN (whichever is sma ller).

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 82Rises in AST/AL T and TBili separated b y more than a few w eeks should be assessed 
individually  based on clinical judgment; any  case where uncertaint y remains as to whether it 
repres ents a potential Hy’s law case should be reviewed with the sponsor.
The participant should return to the investigator site and be eva luated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal resu lts.  This evaluation should 
include laboratory  tests, detailed history , and physical assessment. 
In addition to repeating measurements of AST and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, CK, direc t and indirect 
bilirubin , GGT, PT /INR, total bile acids, 
and alkaline phosphatase.  Consideration shou ld 
also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood 
for further testing, as needed, for further contemporaneo us anal yses at the time of the 
recognized initial abnormalities to determine etiology .  A detailed his tory, including relevant 
information, such as review of ethanol, acetaminophen /paracetamol (either by  itself or as a 
coformulated product in prescription or over -the-counter medi cations) ,recreational drug, 
supplement (herbal) use and consumption, family  history , sexual history , travel history , 
history  of contact with a jaundiced person, surgery , blood transfusion, history  of liver or 
allergic disease, and potential occupational e xposure t ochemicals, should be collected.  
Further testi ng for acute hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  
tract) and collection of serum sample s for acetaminophen/paracetamol drug and/or protein 
addu ct levels may be warrant ed. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be consid ered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  Such potent ial DILI 
(Hy’s law) 
cases are to be reported as SAEs, irr espective of availability of all the results of the 
investigations performed to deter mine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confir med case onl y after all results o f
reasonable investigations have been received a nd have excluded an alternative etiology .

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 8310.7. Appendix 7: ECG Findings of Potential Clin ical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or by≥60msecfrom baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate:
ie,rate<120 bpm .
New -
onset typeI second - degree (Wenckeb ach) AV block of >30 seconds’ duration.
Frequent PVCs, triplets , orshort intervals (<30 seconds) of consecutive ventricular 
complexes .
ECG F indings That May Q ualify as SAEs
QTcF prolongation >500 ms ec.
New ST- T changes suggestive of my ocardial ischemia .
New -onse t l eft bundle branch block (QRS >120 msec).
New -onset right bundle b ranch block (QRS >120 ms ec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented periods 
of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an escape rhy thm 
that is below the AV node. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with 1 or more pauses of at le ast 5 seconds or longer. 
Atrial f lutter or fibrillatio n,with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant symp toms or lasting >1 minute) .
Ventricular r hythms >30 seconds’ duration, including idiovent ricular rh ythm (heart 
rate <40 bpm), accelerated idioventricular rh ythm (HR > 40bpm to <100 bpm),and 

PF-07258669
Protocol C4541001
Final Protocol Amendment 1 , 09November2020
PFIZE R CONFIDE NTIAL
Page 84monomorphic/poly morphic ventricular tach ycardia (HR >100 bpm (suc h as
torsades de pointes) ).
Type IIsecond -degree (Mobitz II)AVblock.
Complete (third
-degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pa uses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion .
Ventricular fibrillation/ flutter .
At the di scretion of the inve stigator, an y arrh ythmia classified as an adverse 
experience .
The en umerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and Pfizer st udy team ,and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.

PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 85     
     
 
 
 
 
 CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 86 
 
 
 
 
 CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 87     
   
 
 CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 88 
  
 
 CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 8910.10. Appendix 10: Abbreviations
The following is a list of abbreviations that may be used in the protocol.
Abbreviation Term
Abs absolute
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the curve
AUC 24 area under the curve from time=0 to time=24 hours post dose
AUC last area under the plasma concentration-time profile from time 0 to the 
time of the last quantifiable concentration
AUC inf area under the plasma concentration-time profile from time 0 
extrapolated to infinite time
AV atrioventricular
β-hCG beta-human chorionic gonadotropin
BMI body mass index
BP blood pressure
bpm beats pe rminute
BUN blood urea nitro gen
Ceff efficacious concentration
CFR Code of Federal Regulations
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration
Clast last quantifiable concentration
Cmax maximum observed concentration
CO 2 carbon dioxide (bicarbonate)
COVID -19 Coronavirus Disease 2019
CRF case report fo rm
CRO contract research organization
CRU clinical research unitCCI
CCI
CCI
CCI
CCI
C
CICCI
CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 90Abbreviation Term
CSR clinical study report
CT clinical trial
CTMS clinical trial management system
DC discontinuation
DILI drug-i nduced liver injury
DMC data monitoring committee
EC ethics committee
ECG electrocardiogram
eCRF electronic case report form
EDP exposure during pregnancy
EDR extemporaneous dispensing record
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
ET early termination
EU European Union
EudraCT European Clinical Trials Database
FSH follicle- stimulating h ormone
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
GLP Good Laboratory Practice
GPCR G- protein coupled receptor
HBcAb hepatitis B core antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCVAb hepatitis C antibody
HDL high-density lipoprotein
HIPAA Health Insurance Portability and Accountability Act
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therapy
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation
ID identificationCCI
C
CI
CCICCI
C
CC
CI
C
C
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 91Abbreviation Term
IND investigational new drug 
INR international normalized ratio
IPAL Investigational Product Accountability Log
IQMP integrated quality management plan
IRB institutional review board
IV intravenous
kel elimination rate constant
LBBB left bundle branch block
LFT liver function test
LDL low-densit y lipoprotein
MC1R melanocortin-1 receptor
MC2R melanocortin-2 receptor
MC3R melanocortin-3 receptor
MC4R melanocortin-4 receptor
MC5R melanocortin-5 receptor
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean cor puscular volume
msec millisecond
N/A not applicable
NOAEL no-observed-adverse-effect level
NOEL no-observed-effect-level
PCR polymerase chain reaction
PCRU Pfizer clinical research unit
PD pharmacodynamic(s)
PI principal investigator
PIMS Phase 1 Management System
PK pharmacokinetic (s)
PR pulse rate
PT prothrombin time
PVC premature ventricular contraction/complex
QTc corrected QT
QTcF corrected QT (Fridericia method)
RBC red blood cellC
CI
CCI
CCI
CCIC
CIC
CI
CCI
CC
I
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 92Abbreviation Term
SAE serious adverse event
SAP statistical analysis plan
SCr serum creatinine
SoA schedule of activities
SOP standard operating procedure
SPF sun protection factor
SRSD single reference safety document
SUSAR suspected unexpected serious adverse reaction
t½ terminal half-life
TBili total bilirubin
THC tetrahydrocannabinol
Tmax time for C max
ULN upper limit of normal
US United States
UV ultraviolet
WBC white blood cell
WOCBP woman of childbearing potentialCCI
CCI
CC
I
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 9311. REFERENCES
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C
CI
CCI
CCI
CCI
CCI
PF-07258669
Protocol C4541001Final Protocol Amendment 1, 09 November 2020
PFIZER CONFIDENTIAL
Page 94 
 
 
 
 
 
 
 
 
 
 
 CCICCICCI
CCI